Optimisation of a whole blood flow cytometry assay to aid in the diagnosis of tuberculosis by detecting intracellular cytokines released by CD4+ T-cells by Snyders, Candice Irene
Optimisation of a whole blood flow cytometry assay 
to aid in the diagnosis of Tuberculosis by detecting 
intracellular cytokines released by CD4
+
 T-cells. 
By 
Candice Irene Snyders 
Thesis presented in partial fulfilment of the requirements for the degree of Master of 
Science (Haematological Pathology) in the Faculty of Medicine and Health Sciences 
at Stellenbosch University 
Supervisors: Dr Ravnit Grewal & Dr Carmen Swanepoel 
March 2017 
The financial assistance of the National Research Foundation (NRF) towards this 
research is hereby acknowledged. Opinions expressed and conclusions arrived at, 
are those of the author and are not necessarily to be attributed to the NRF.
i 
Declaration 
By submitting this thesis electronically, I declare that the entirety of the work 
contained therein is my own, original work, that I am the sole author thereof (save to 
the extent explicitly otherwise stated), that reproduction and publication thereof by 
Stellenbosch University will not infringe any third party rights and that I have not 
previously in its entirety or in part submitted it for obtaining any qualification. 
Signature: 
Date:  March 2017 
Copyright © 2017 Stellenbosch University
All rights reserved
Stellenbosch University  https://scholar.sun.ac.za
  
ii 
 
Abstract 
Background: South Africa (SA) sees 8 million new Tuberculosis (TB) cases each 
year and has a significant problem with Human Immunodeficiency Virus (HIV) and 
TB co-infection. Latent TB infection (LTBI) is described in persons infected with 
mycobacterium tuberculosis (M.tb) but shows no signs and symptoms of active 
disease. HIV
+ 
individuals with LTBI can develop active TB infection more readily than 
that of HIV
-
 individuals. Gold standard methods for diagnosing active disease have 
been criticized for, among other things, their lengthy turnaround times. Currently 
there is no gold standard for the diagnosis of LTBI. Flow cytometry allows one to 
measure cytokine responses in CD4
+
 T-cells following overnight stimulation with TB 
antigens ESAT-6 and CFP-10 (E/C). Studying these cytokine expression patterns 
will make it possible to classify patients into active disease vs. LTBI. 
Methods:A total of 18 TB
+
 patients which included 6 HIV
+
patients, were recruited 
from Tygerberg Hospital, Western Cape. A whole blood no-centrifuge intracellular 
flow cytometry assay was optimised to study the cytokine expression patterns in 
CD4
+
 T-cells that have been stimulated with TB antigens and Staphylococcus 
Enterotoxin B (SEB), following an 18 hour overnight incubation. CD3
+
CD4
+
 T-cells 
were delineated into the following subsets: naïve (TN) (CD45RO
-
CD27
+
), central 
memory (TCM) (CD45RO
+
CD27
+
),effector memory (TEM)(CD45RO
+
CD27
-
) and 
terminally differentiated effector memory cells (TDEM) (CD45RO
-
CD27
-
). The 
expression patterns and effect of stimulation on cytokines IFN-γ and TNF-α as well 
as T-cell exhaustion marker TIM3, was assessed.  
Results: This study has demonstrated higher levels of IFN-γ expression in the 
control group compared to that of the TB positive patients (median %IFN-γ 2.960 ± 
3.51 versus patient 2.370 ± 2.07; p=0.2800). TNF-α had higher expression in the 
patient group compared to the control subjects (median %TNF-α 2.415 ± 2.60 versus 
control 1.340 ± 1.86; p=0.1729). Dual expression of cytokines was almost similar in 
the two groups (control median % IFN-γ+TNF-α+ 0.5400 ± 0.36 versus patient 0.8550 
± 0.60; p=0.3961). TIM3 expression was not significantly different between the four 
T-cell subsets (median TN 0.0750 ± 1.89, TCM 0.3400 ± 4.28, TEM 0.0850 ± 2.73, 
TDEM 0.1600 ± 1.93; p= 0.5877). When comparing the subset distribution in the 
patient group, TN cells were the most abundant (median 47.48 ± 20.96) followed by 
TEM cells (median 21.92 ± 13.25), TDEM cells (median 13.02 ± 20.13) and finally TCM 
cells (median 11.51 ± 8.62). These results showed a significant difference in 
expression between the four groups (p=<0.0001). 
Conclusion: Through careful titration of antibodies and relevant optimisation steps, 
we established a flow cytometry assay that may be used to study cytokine patterns 
in TB patients. The increased TNF-α only expression in the patient group is 
suggestive of active TB and the increased IFN-γ in the control group could indicate 
BCG vaccination. TIM3 would be a useful marker in a larger HIV
+
 cohort of patients 
as this will allow identification of functionally exhausted T-cells. In SA, HIV 
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prevalence is rising and this assay proves its suitability by using minimal volumes of 
whole blood rather than sputum. By generating intracellular cytokine profiles one 
would be able to distinguish between active and LTBI which would aid in treatment 
management of patients. 
 
Opsomming 
Agtergrond: Suid-Afrika (SA) het 8000000 nuwe Tuberkulose (TB) gevalle elke jaar 
en het 'n groot probleem met MIV en TB mede-infeksie. Latente TB-infeksie (LTBI) 
word beskryf in persone wat besmet is met Mycobacterium tuberculosis (M.tb), maar 
toon geen tekens en simptome van 'n aktiewe siekte. MIV
+ 
individue met LTBI kan 
aktiewe TB-infeksie meer geredelik as dié van MIV
-
individue ontwikkel. Goud 
standaard metodes vir die diagnose van aktiewe siekte is gekritiseer vir, onder 
andere, hul lang omkeertye. Daar is tans geen goue standaard vir die diagnose van 
LTBI. Vloeisitometrie laat mens toe om sitokien uitdrukking in CD4
+
 T-selle te meet 
na oornag stimulasie met TB antigene ESAT-6 en CFP-10 (E / C). Die bestudering 
van hierdie sitokien uitdrukking patrone sal dit moontlik maak om pasiënte te 
klassifiseer as aktiewe siekte of LTBI. 
Metodes: 'n Totaal van 18 TB pasiënte wat 6 MIV
+ 
pasiënte insluit, is gewerf uit die 
Tygerberg-hospitaal, Wes-Kaap. 'N Heel bloedgeen-centrifuge intrasellulêre 
vloeisitometrie toets is geoptimaliseer om die sitokien uitdrukking patrone in CD4
+ 
T-
selle wat reeds gestimuleer word met TB antigeneen Staphylococcus enterotoksien 
B (SEB), na aanleiding van 'n 18 uur oornag inkubasie te bestudeer. CD3
+
CD4
+
 T-
selle is afgebaken in die volgende onderafdelings: naïef (TN) (CD45RO
-
CD27
+
), 
sentralegeheue (TCM) (CD45RO
+
CD27
+
), effektorgeheue (TEM) (CD45RO
+
CD27
-
) 
enterminaal gedifferensieerde effektorgeheueselle (TDEM) (CD45RO
-
CD27
-
). Die 
uitdrukkings patrone en effek van stimulasie op sitokiene IFN-γ en TNF-α asook T-
seluitputtingmerker TIM3, is bestudeer. 
Resultate: Hierdie studie het hoër vlakke van IFN-γ uitdrukking getoon in die 
kontrole groep in vergelyking met dié van die TB-positiewe pasiënte (gemiddelde% 
IFN-gamma 2,960 ± 3,51 vs pasiënt 2,370 ± 2,07; p = 0,2800). TNF-α het 
hoëruitdrukking in die pasiëntgroep in vergelyking met die kontrole kandidate 
(mediaan% TNF-α 2,415 ± 2,60 teen beheer 1,340 ± 1,86; p = 0,1729). Dubbele 
uitdrukking van sitokiene was amper soortgelyk in die twee groepe (kontrole 
mediaan% IFN-γ + TNF-α + 0,5400 ± 0,36 teen pasiënt 0,8550 ± 0,60; p = 0,3961). 
TIM3 uitdrukking was nie beduidend anders in die vier T-sel deel versamelings nie 
(mediaan TN 0,0750 ± 1.89, TCM 0,3400 ± 4.28, TEM 0,0850 ± 2,73, TDEM 0,1600 ± 
1,93; p = 0,5877). Wanneer die vergelyking van die subset verspreiding in die 
pasiëntgroep gedoen was, het TNselle die meeste voorgekom (mediaan 47,48 ± 
20,96) gevolg deur TEM selle (mediaan 21,92 ± 13,25), TDEM selle (mediaan 13,02 
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± 20,13) en uiteindelik TCM selle (mediaan 11,51 ± 8,62 ). Hierdie resultate toon 'n 
beduidende verskil in die uitdrukking tussen die vier groepe (p = <0,0001). 
Gevolgtrekking: Deur versigtige titrasie van teenliggaampies, ens het ons gestig 'n 
vloeisitometrietoets wat gebruik kan word om sitokien patrone te studeer in TB-
pasiënte. Die verhoogde enkele TNF-α uitdrukking in die pasiëntgroep is n 
aanduiding van aktiewe TB en die verhoogde IFN-γ in die kontrolegroep kan 
moontlike BCG inenting aan dui. TIM3 sou 'n nuttige merker in 'n groter MIV
+ 
kohort 
van pasiënte wees, want dit sal die identifisering van funksioneel uitgepute T-selle 
identifiseer. In SA, is die voorkoms van MIV stygend en hierdie toets bewys sy 
geskiktheid deur die gebruik van  minimale volumes van volbloed, eerder as sputum. 
Deur die opwekking van intrasellulêre sitokien profiele sou 'n mens in staat wees om 
te onderskei tussen aktiewe en LTBI wat sou help met die behandeling van pasiënte 
.  
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Chapter 1 - Literature review 
1.1 Introduction 
The World Health Organization (WHO) declared Tuberculosis (TB) a global health 
pandemic more than 20 years ago. However despite recent advances in diagnosis 
and clinical management, TB to date still remains the second deadliest infectious 
disease after acquired immune deficiency syndrome (AIDS) (Shu et al., 2012; 
Elkington 2013). Mycobacterium Tuberculosis (M.tb) bacilli gets transmitted by the 
inhalation of infected aerosol droplets that is produced through the coughing of 
persons with active pulmonary disease. In most cases this transmission is done 
without detection, since the patient’s signs and symptoms are not specific to TB. 
Factors such as overcrowded areas, poor hygiene and sanitation, poverty and 
homelessness, alcoholism, diabetes and age, to mention a few, contribute to the 
development and spread of this disease and play a huge role in the clinical 
management and finally the disease outcome (Lienhardt, 2001; Betsou et al., 2011; 
Shu et al., 2012). 
In addition, due to a non-specific clinical picture and diagnostic complications, the 
pathogenesis of TB is further hampered by human immunodeficiency virus (HIV) co-
infection (Shankar et al., 2014). In South Africa (SA) alone more than 70% of people 
living with TB also have HIV (For, 2011). Immune function of the host is weakened 
by the co-existence of this duo, as HIV depletes the body’s CD4+T-cells, which in 
turn is needed to help control TB. HIV also hampers cytokine production and 
macrophage function, key features necessary in the immune response, which leads 
to the inability of the host to suppress latent or initial TB infection (Diedrich & Flynn 
2011; Pawlowski et al. 2012). In addition, HIV increases reactivation of latent TB 
infection up to 20 times and catalyses the progression of TB infection to active 
disease and similarly TB exacerbates HIV infection (Pawlowski, Jansson, Sköld, 
Rottenberg, & Källenius, 2012). For the purpose of this thesis, this chapter will give a 
condensed and simplified overview of TB, the effect on the immune response, TB 
diagnostics, HIV co-infection and flow cytometry in order to provide context for later 
chapters. 
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1.2 Background 
1.2.1 Epidemiology 
The WHO states that; TB is responsible for ill health amongst millions of people each 
year and remains one of the deadliest communicable diseases in the world. In 2014, 
an estimated 9.6 million people developed TB and 1.5 million died from the disease, 
of whom 400 000 were HIV – positive(WHO, 2015). TB incidence globally (Figure 
1.1) is declining slowly each year and it’s estimated that 37 million lives were saved 
between 2000 and 2013 through effective diagnosis and treatment.At present, a six 
month regimen of four first - line drugs: Isoniazid, Rifampicin, Ethambutol and 
Pyrazinamide is the recommended treatment.The treatment success rate of newly 
diagnosed TB cases was 86% in 2013 (WHO 2014).  
 
 
Figure 1.1Global Tuberculosis burden 2014(Image taken from WHO 2015) 
 
South Africa is one of five countries experiencing the highest TB incidence globally 
with800–1,200 per 100,000 in 2012, which coincided with the onset of the HIV 
pandemic (Vynnycky et al., 2015). Ninety percent of TB cases in 2013 had co - 
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infection with HIV while 26 023 cases of multi – drug resistant TB (MDR-TB) was 
reported in SA. South Africa was also one of three countries with the largest increase 
in MDR-TB between 2011 and 2012. Treatment for MDR-TB lasts 20 months and 
treatment success rates are much lower (Tuberculosis & Guidelines, 2014). An 
estimated 9.7% of people with MDR-TB have extensively drug-resistant TB (XDR-
TB) (WHO, 2015). XDR-TB defined as: MDR-TB plus resistance to at least one 
fluoroquinolone and a second-line injectable, had been reported by 105 countries 
globally by the end of 2014 (WHO, 2015). Although the WHO 2015 report does not 
give exact figures for the successful treatment of XDR-TB, it does make mention that 
the high mortality rate (47%) of XDR-TB patients in SA is most likely due to the rising 
level of HIV co-infection (WHO, 2015).  
 
1.2.2 Tuberculosis Pathogenesis 
TB infection is a marked serious of events, which starts off by a patient with 
pulmonary TB coughing and subsequently releasing the M.tb bacilli into the 
atmosphere whereby the infectious droplets are then inhaled by others in close 
proximity (Cooper, 2009). The innate and adaptive immune systems work together to 
eliminate the invading pathogen from the lungs resulting in the formation of a 
granuloma. A granuloma is made up of a mass of cells such as lymphocytes, 
macrophages, dendritic cells, neutrophils and fibroblasts and often has a necrotic 
centre and multiple granulomas can be seen in patients with active TB (Diedrich & 
Flynn, 2011). Although these granulomas may heal, it leaves a calcified Ghon focus 
in the lower zones of the lungs which mark the initial site of infection (Cooper 2009; 
Elkington 2013).  In latent TB infection, the bacteria persist within the granuloma, but 
the host manages to effectively resist the bacteria. As seen in Figure 1.2, when the 
granuloma’s structure or function becomes compromised it leads to either latent TB 
infection, disseminated TB or active disease (Diedrich & Flynn, 2011).  
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Figure 1.2Pathophysiology of tuberculosis: (A) M.tb bacilli inhaled in droplet formation, (B) innate 
and adaptive immune system working together to contain M.tb bacilli in the granuloma, (C) when host 
becomes immune compromised the granuloma ruptures and is spilled in to the atmosphere through 
coughing by the host or spread to other organs (Image taken from Knechel 2009). 
 
 
Alveolar macrophages are the initial target cells for mycobacteria bacilli and are 
activated by cytokines, enabling them to perform bactericidal effector functions 
(Pawlowski et al., 2012). Dendritic cells phagocytose the M.tb bacilli in the lung 
tissue and move to the draining lymph nodes whereby the adaptive immune 
response is initiated and subsequently activates naïve T-cells(Chackerian et al., 
2002). The role of these activated T-cells will be discussed in section 1.2.2.1  
 
1.2.2.1 Cell – mediated immunity and TB 
T-cells play a major role in containing or spreading TB infection as they are forceful 
interferon gamma (IFN-γ) producers, which in turn activates crucial anti–
mycobacterial activities of macrophages. IFN-γ together with tumor necrosis factor 
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alpha (TNF- that control intracellular infections, and lymphotoxin (LT)-α3,  regulate 
the formation of granulomas and maintain its structural integrity (Kaufmann, 2001). 
CD4
+
T helper cells or CD8
+
cytotoxic T-cells can produce two or more cytokines at 
the same time and are known to be polyfunctional. Polyfunctional cells have greater 
effector and proliferative functions as compared to mono- or bi-functional cells and 
produce IFN-γ, TNF and interleukin 2 (IL-2) (Seder et al. 2008; Jasenosky et al. 
2015). T helper 1 – type CD4+ T-cells are the hallmark cells for controlling the 
pathogenesis of TB (Jeong et al., 2014). Previous studies have shown that CD4
+ 
T-
cells that are mono- or bi-functional, i.e. expressingeither TNF-α alone, or both TNF-
α and IFN-γ respectivelyare associated with active TB disease and they act 
synergistically to kill pathogens. On the contrary larger numbers of polyfunctional 
CD4
+
T-cellswith the phenotype TNF
+
IFN-γ+IL-2+,were found predominantly in 
patients with latent TB infection, as well as patients on TB treatment (Jasenosky et 
al., 2015).However, Caccamo et al (2010) has found that patients with active TB 
disease showed a higher frequency of polyfunctional cells (Caccamo et al., 2010). 
Antigenic stimulation (with cytomegalovirus or Mycobacterium bovis bacillus 
Calmette–Guérin (BCG) vaccine) of T-cells also leads to activation of the subset 
cells (central memory and effector memory) into effector CD4
+
T-cells which lead to 
their death. However, the extent to which cells differentiate depend on initial antigen 
exposure or innate – immune factors found in the cells’ surrounding environment.  
A study done by Seder et al., 2008 has demonstrated as seen in Figure 1.3, that 
CD4
+
T-cells mostly express TNF and can co-express IL-2 whether IFN-γ is 
expressed or not. However, if IL-2 is expressed regardless of TNF, the cell will 
survive and can be sustained for longer and subsequently differentiate into IFN-γ 
producing T-cells, because on its own, IL-2 has little effector function (Darrah et al., 
2007)  Hence, memory CD4
+
T-cells with effector function secrete IL-2 or TNF or both 
simultaneously. T-cells can produce IFN-γ and TNF without IL-2. T-cells that secrete 
IFN-γ only, do not survive for long as memory T-cells and are usually at the final 
stage of T cell differentiation (Seder et al., 2008). 
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Figure 1.3Linear model for T-cell differentiation (a) CD4
+
T-cells gain function as they differentiate 
until they reach the optimal stage of their effector function, which is to produce cytokines. The last 
stage of differentiation is reached under continued antigenic stimulation whereby T-cells produce only 
IFN-γ and have a relatively short life span(Image taken from Seder et al. 2008).TCM – central memory 
CD4
+
 T-cell; TEM effector memory CD4
+
 T-cell. 
 
In conclusion, CD4
+
T-cells that differentiate into polyfunctional cells secreting IFN-γ, 
TNF and IL-2, have three possible outcomes: (i) they can continue as memory or 
effector cells; (ii) they can differentiate into less functional T-cells or (iii) following 
activation they can undergo apoptosis and die. An ideal cell population deemed 
effective in combatting infection should be multifunctional and be able to rapidly 
mediate effector function and have a reservoir of memory T-cells. (Darrah et al., 
2007;Seder et al., 2008). 
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1.2.2.2 T-cell subsets 
CD4
+
 T-cells differentiate into different types of T-helper (Th) cells which each 
produce cytokines that assist other cells to perform different functions. Figure 1.4 
shows the five lineages of T-helper cells which are Th1, Th2, Th17, T-follicular cells 
(Tfh) and T-regulatory (Tregs) cells. These groups of cells each perform a different 
function (Spellberg & Edwards, 2001). 
 
T helper cell subsets 
Th1 
Th1 cells are the hallmark cells for controlling the pathogenesis of TB and are known 
to be the leading regulators of type 1 immunity (Jeong et al., 2014)(Appay et al., 
2008). Th1 cells produce IFN-γ, TNF-α, IL-2 and lymphotoxin-α. The functions of 
these cytokines are discussed in Chapter 1, section 1.2.2.1, page 7-9. Another 
cytokine produced in this group is IL-12 which plays a role in the polarisation of Th1 
cells and IFN-γ induction. It also increases cytotoxicity by stimulating the proliferation 
of antigen-specific cytolytic T cells and NK cells (Appay et al., 2008) 
 
Th2 
Th2 cells produce IL-4, IL-5, IL-10 and IL-13. They also produce TNF-α but not IFN-
γ. The role of these cytokines are briefly describes as follows : 
 IL-4 
IL-4 is increased during active TB and is said to play a pathogenic role during the 
late phase of TB infection. IL-4 down regulates Th1 responses (Sakamoto K, 2012) 
 IL-5 
Plays a role in the differentiation and activation of eosinophils in the bone marrow 
(Sanderson 1990) 
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 IL-10 
IL-10’s function is to deactivate macrophages and reduce Th1 responses. It limits 
antigen presentation, decreases reactive oxygen intermediates (ROI) and reactive 
nitrogen intermediates (RNI) and these subsequently have a major effect on the 
innate and adaptive immune response in TB. IL-10 is an immunosuppresive cytokine 
that has its effect on macrophages, monocytes, dentritic cells and T-cells. IL-10 
plays an important role in TB and has been identified as a biomarker and a correlate 
of susceptibility to TB (Beamer et al., 2008). 
 IL-13 
IL-13 is involved in IgE synthesis and subsequently allergic responses and plays a 
role in airway inflammation (Wynn, 2003). 
 
Th17 
Th17 cells develop in the presence of low amounts of TGF-β, IL-1β and TNF and this 
process is initiated by IL-6 or IL-21. The signature cytokines of this group is IL-17, IL-
17F, IL-21 and IL-22. It is suggested that these cells and its produced cytokines have 
a complex role in different infections caused by bacteria, fungi and viruses and they 
play a key role in inducing inflammation and tissue damage in animals in 
autoimmune diseases and infection. There is limited information on human studies 
done on Th17 cytokines, but mouse studies suggest that a high dose of M.tb initiated 
intratracheally was poorly controlled in the absence of IL-17 (Torrado & Cooper, 
2010). 
 
T follicular cells (Tfh) 
Tfh cells fall under the CD4
+
 T-cell subset cells that reside in human secondary 
lymphoid tissues and are responsible for the activation, expansion and differentiation 
of B cells into immunoglobulin secreting cells. This process is facilitated by the 
simultaneous expression of chemokine receptors CXCR5 and the down regulated 
CCR7. Transcription factor Bcl-6 is required for the differentiation of Tfh cells that 
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subsequently express IL-21, however; circulating Tfh cells have proven to lack Bcl-6 
expression (Ma & Deenick, 2014). 
 
T regulatory cells (Tregs) 
Treg cells emerge from the thymus.Upon stimulation they have the phenotype 
CD4
+
CD25
+Foxβ3+ and has been identified as a role player in immune suppression 
of chronic diseases and subsequently the suppression of effector T-cell responses 
during TB infection.Singh et al., (2012) has shown that the Treg cell representation is 
directly proportional to the TB bacillary load or severity of TB infection as the Treg 
numbers have declined after successful TB treatment. (Singh et al., 2012;Lastovicka 
J 2013). 
 
 
Figure 1.4T-cell differentiation pathway. Naïve cells differentiate into the respective effector subset 
cells upon stimulation(Jelley-gibbs et al., 2008). 
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1.2.2.3 Active vs. Latent TB disease 
In latent TB infection (LTBI), M.tb bacilli are able to persist in the body without 
causing illness. The host has no clinical signs or symptoms, is not infectious and 
cannot spread the M.tb bacilli. If the hosts’ immune system becomes compromised, 
progression to active disease occurs. Currently a diagnosis of LTBI is made on the 
bases of a positive tuberculin skin test (TST) and Interferon gamma release assay 
(IGRA), however, these two tests have been criticized for their accuracy and their 
short comings will be discussed in detail later in section 1.2.3 (CDC 2015). 
In active disease the M.tb bacilli overcomes the host’s defence mechanisms and 
multiply in the body. Clinically patients present with symptoms such as fatigue, 
weight loss and coughing and are able to spread the M.tb bacilli to others (CDC 
2015).  
Treatment between the two disease states diverges with regards to the regimen of 
drugs and duration of treatment as detailed below in Table 1.1 (Rovina et al., 
2013).In addition, the presence of HIV further increases the reactivation of latent TB 
infection up to 20 times and catalyses the progression of TB infection to active 
disease, therefore it is imperative to be able to accurately diagnose LTBI (Pawlowski 
et al., 2012).  
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Table 1.1 Treatment regimens for LTBI and active disease 
Latent TB disease 
Drugs Duration Interval Minimum doses 
INH 9 months Daily 
Twice weekly* 
270 
76 
INH 6 months Daily 
Twice weekly* 
180 
52 
INH + Rifampentine 3 months Once weekly 12 
RIF 4 months Daily 120 
Active disease 
Initial phase 
INH 
RIF 
PZA 
EMB 
 
8 weeks 
 
Daily 
 
56 
Continuation phase 
INH 
RIF 
 
18 
 
Daily 
 
126 
INH 
RIF 
18 Twice weekly 36 
Abbreviations: INH – Isoniazid, RIF – Rifampin, PZA – Pyrazinamide, EMB – Ethambutol      
* - Use directly observed therapy (Adapted from CDC 2015). 
 
1.2.3 Tuberculosis Diagnostics 
Despite advances in TB diagnostic techniques, the rate of false negative results 
remains high (Elkington, 2013). Given the high statistics of TB/HIV-1 co-infection, it 
is important to efficiently diagnose latent tuberculosis infection (LTBI), as patients co-
infected, transplant patients and patients receiving immunosuppressive therapies are 
more susceptible to develop active disease. Being able to distinguish between the 
two disease states is imperative as treatment and management of the patient differs 
between the two (Rovina et al., 2013). In Table 1.2 below, the differences between 
the different diagnostic tests are detailed.  
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Table 1.2Differences between different TB diagnostic tests 
Test Specificity Sensitivity Ability 
to 
detect 
LTBI 
Detection of 
Mtb 
resistance to 
RIF and/or 
INH  
Limitations 
TST High in non-
BCG  
Low No No Return visit in 48-72 
for test results 
IGRA High High No No Costly 
Chest X-ray Low Low No No Non confirmatory 
ZN 
microscopy 
Low Low No No Cannot distinguish 
between M.tb and 
other species 
Culture Low Low No No Results take up to 6 
weeks 
NAA High Low No No Costly 
LAM High Low No No Contamination of 
urine samples with 
normal flora – may 
lead to false-positive 
results  
MODS High High No Yes – both Training and 
technical expertise 
needed. Biosafety 
level 3 required 
LED 
microscopy 
Low High No No Fluorescent 
microscope, dark 
room and expensive 
light source required  
GeneXpert High High No Yes – RIF 
only 
Costly; Sufficient 
laboratory 
infrastructure and 
staff training required 
Abbreviations: TST – Tubercilin skin test, IGRA – Interferon gamma release assay, ZN – 
Ziehl Nielsen, NAA - Nucleic Acid Amplification testing, LAM – lipoarabinomannan, MODS -  
microscopic Observation Drug Susceptibility, LED – light emitting diode. (Adapted from Sia & 
Wieland 2011) 
 
A diagnosis of LTBI is made on the bases of a negative Mantoux TST and IGRA, 
whereas active disease relies on chest x-rays suggestive of pulmonary TB and a 
positive Ziehl-Neelsen (ZN) acid fast bacilli (AFB) smear and culture (Sia & Wieland, 
2011). The ZN acid fast stain, a microscopic test recommended by the WHO as a 
diagnostic tool, especially in resource poor settings, has both low sensitivity and 
specificity. With a detection limit of 5000-10 000 M.tb bacilli/ml per sample, a false 
negative result is more common in HIV patients, children and the elderly due to a low 
bacillary load and difficulty to produce sputum. Likewise, culture techniques, 
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regarded as the gold standard for TB diagnosis, has its own draw backs despite the 
fact that it requires only 10 M.tb bacilli/ml as compared to the ZN.  It takes 4 – 8 
weeks for the bacteria to grow which subsequently delays the onset of treatment 
(Muwonge et al., 2014).  
Similarly the TST, dating back to the early 1930’s, is still a current diagnostic tool to 
identify TB infection despite several limitations on the use of this test (Starke, 1993). 
This includes return visits from the patient, cross-reactivity with non-tuberculosis 
mycobacteria and the Bacille Calmette-Guerin (BCG) vaccine (vaccine containing 
Mycobacterium Bovis) as well as inter-reader variability. In addition, a major 
limitation of this test is the poor sensitivity in immune compromised patients as well 
as the inability to distinguish between latent TB and active disease (Frahm et al., 
2011).   
On the other hand the IGRAs was developed to compensate for some of the TST’s 
short comings as it is more reliable and highly specific (Sester et al., 2011). IGRAs 
measure the expression of IFN-γ released by T-cells following stimulation of the 
peripheral blood with 6-kDa early secretory antigenic target (ESAT-6) and 10-kDa 
culture filtrate antigen (CFP-10) which are encoded in the region of difference 1 of 
the mycobacterial genome. The specificity of this test is due to the fact that neither 
ESAT-6 and CFP-10 are found in BCG vaccine strains or in non-tuberculous 
mycobacteria (Rovina et al., 2013). There are currently two IGRAs namely, the 
QuantiFERON-TB Gold In –Tube test (QFT-GIT) and  the T-SPOT.TB test (T-Spot) 
(Sester et al., 2011). Since these tests measure IFN-γ as a single parameter of T-cell 
activation, it will only indicate  either the presence or absence of TB infection, and 
cannot distinguish between active from latent TB, which discredits its specificity but 
compliments its sensitivity (Rutledge et al., 2010). 
In 2010, the WHO endorsed an automated, rapid molecular test that can test for TB 
and Rifampicin (RIF) resistance simultaneously (WHO, 2013). This real-time PCR 
assay - GeneXpert MTB/RIF amplifies the MTB specific sequence of the rpoB gene 
that detects mutations within the rifampin-resistance determining region. The 
instrument which takes 2 hours to generate a result, uses a disposable cartridge 
containing all needed reagents to simultaneously perform bacterial lysis, nucleic acid 
extraction, amplification and amplicon detection (Boehme et al., 2010). Although this 
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assay is more sensitive and replaced the smear microscopy as the primary 
diagnostic test in SA, it is very expensive making it inaccessible to most endemic 
regions (WHO, 2013). 
Nucleic Acid Amplification testing (NAAT), used to test for pulmonary TB, detects 
M.tb ribosomal RNA directly from both AFB smear positive and negative patients 
with suspected TB using the Enhanced Amplified Mycobacterium Tuberculosis Direct 
(MTD) test. The AmplicorMtb test on the other hand is able to detect the Mtb DNA in 
AFB smear – positive respiratory specimens. The two tests – NAAT and AFB 
smears, always go hand in hand. If both tests are positive, this is indicative of TB. 
However, if the results are discrepant, doctors make a decision together with the 
culture results and clinical symptoms (Sia & Wieland, 2011). 
Another diagnostic test involves lipoarabinomannan (LAM), a glycoprotein found in 
the cell wall of Mtb, which is released from active or degrading Mtb cells during 
active TB infection. LAM antigens are detected in patients’ urine and a positive result 
indicates active TB disease. This test has the advantage of easier sample collection, 
especially in children as urine is safer to process and store and infection control 
procedures are minimal. With regards to specificity, LAM assays is comparable to 
smear microscopy, however it has a higher and more reliable sensitivity and has the 
advantage of detecting disseminated TB. However, the greatest diagnostic challenge 
of differentiating between active and latent disease, is still not addressed by this 
assay (Minion et al., 2011).  
Fluorescent light emitting diode (LED) microscopy uses a fluorochrome stain – 
auramine that is more sensitive than the ZN stain and less time consuming. 
However, the need for expensive equipment and a dark room makes this test less 
popular (Wilson, 2011).  The microscopic Observation Drug Susceptibility (MODS) 
Assay is a broth microtitre method that detects M.tb bacilli and Isoniazid (INH) and 
Rifampin resistance (Moore et al., 2006). M.tb grows faster in liquid than on solid 
media, giving this assay the advantage over the conventional culture method. Anti-
TB drugs are also included in the assay which allows for rapid detection of drug 
resistance. However the use of MODS is not so popular as it requires testing in a  
biosafety level 3 facility, equipment and supplies are expensive and is therefore not 
available at smaller laboratories (Wilson, 2011). 
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Similar to IGRAs, Intracellular cytokine flow cytometry (ICCFC) has a further 
advantage of being able to measure multiple cytokines released by specific T-cells 
after stimulation by M.tb antigen (Kim et al., 2014). It is a method used for counting 
and sorting of microscopic particles and examining the characteristics of individual 
particles that flow in a single file suspended in a stream of fluid (Brown & Wittwer, 
2000). The difference in size and internal complexity of the cell can be distinguished 
from light scattered at different angles when compared to light emitted from 
fluorescently labelled antibodies, which is able to identify cell surface and 
cytoplasmic antigens. Due to these unique characteristics, flow cytometry is a 
powerful tool to use for detailed analysis of complex populations in a short period of 
time (Orfao et al., 1995). The results obtained upon analysis may be both 
quantitative and qualitative (Brown & Wittwer, 2000). Flow cytometry can be used to 
measure the morphological and cell surface antigen characteristics of a single cell. It 
is able to measure the cell size and inner complexity of the cell such as the shape of 
the nucleus, the roughness of the membrane and the type of cytoplasmic granules 
(Brown & Wittwer, 2000). 
Flow cytometry is able to enumerate cells and detect which cells specifically release 
cytokines in response to TB antigen stimulation (Maino & Picker, 1998). It can rapidly 
and simultaneously determine cytokine production of defined leucocyte subsets in 
peripheral blood and T-cells at inflammatory sites. The presence of variable 
concentrations of cellular or soluble receptors also does not compromise the 
quantitation of cytokine production (Maino & Picker, 1998). With flow cytometry it is 
possible to directly detect intracellular cytokine expression with fluorochrome–
conjugated anti–cytokine antibodies after short periods (4–6h) of activation with 
different stimuli (Picker et al., 2016). The length of activation may vary depending on 
the individual need of each laboratory. The sensitivity of cytokine detection is 
enhanced by disruption of cytokine secretion after stimulation by adding the 
secretion inhibitor Brefeldin A, followed by a fixation and permeabilization step in 
order to stain intracellularly (Maino & Picker, 1998). Another fixation step follows and 
cells may now be acquired on the flow cytometer. The length of time for the entire 
process to complete is dependent on optimisation of the assay. Optimisation of the 
assay will be discussed in section 2.8. For the purpose of this thesis, flow cytometry 
and its potential as a diagnostic tool will be further investigated in this project. As 
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many flow cytometry studies have investigated measurements on both whole blood 
and peripheral blood mononuclear cells (PBMC’s), we further discuss these options 
to determine which of the two is best to use during optimization. 
 
1.2.4 TB and HIV co-infection 
As mentioned in section 1.1, a large percentage of people within SA also have HIV. 
Figure 1.5, below demonstrates the coaction of TB and HIV co-infection. Following 
the phagocytosis of M.tb, macrophages become activated and secrete cytokines: 
TNF-α, interleukin 1 beta (IL-1β) and interleukin 6 (IL-6) which in turn increase HIV-1 
replication (Shankar et al., 2014). Effector T-cells however, reach a state of immune 
exhaustion following continual activation and cytokine secretion. This renders these 
cells dysfunctional or unresponsive to any downstream antigen stimulation. As HIV 
infection continues, immune exhaustion become more evident as T-cell effector 
functions such as its cytokine cytotoxic potential become diminished and progression 
to AIDS occurs (Shankar et al., 2014). AIDS is characterised by the hallmark loss of 
CD4
+
T-cells and this contributes to the reactivation of latent TB and makes the host 
susceptible to new M.tb infection.  
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Figure 1.5Epidemiological coaction of Tuberculosis and HIV(Vermund & Yamamoto, 2007) 
 
HIV exacerbates TB by tipping the Th1/Th2 cell balance and impairs the TNF-
mediated macrophage response to MTB and this leads to survival of the bacteria 
(Patel et al., 2007;Pawlowski et al., 2012).  
Granuloma formation in TB infection, localizes the infection, prevents the spread of 
bacilli and offers host protection. HIV compromises granuloma structural integrity. A 
granuloma typically has a caseous necrotic centre, however in patients with AIDS, a 
dominant granulocytic infiltrate and necrosis replaces this normal feature (Pawlowski 
et al., 2012). Diedrich & Flynn, 2011 has divided the granuloma disruption into four 
steps: (i) viral load increase in the involved tissues, that result in (ii) significant loss of 
CD4
+
T-cells, alongside (iii) macrophage dysfunction and (iv) disruption of M.tb 
specific T-cell function ultimately causing functional and inimical changes within the 
granuloma. HIV fuels this defect and results in systemic disease characterized by 
multiple organs containing defective granulomas that lead to the development of 
more diffuse lesions (de Noronha et al.,2008). This disease state is known as extra 
pulmonary TB or disseminated disease. As M.tb replication is now increased, 
mononuclear cells become activated resulting in increased HIV replication and 
subsequently increased  HIV viral load at the site of TB infection (Lawn, 2005). 
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1.2.5 Markers of T cell exhaustion 
One of the fundamental hallmarks of infections particularly in the case of HIV as well 
as TB is “T cell exhaustion”. This is described as the inability of cells to produce 
cytokines, to proliferate and to survive in the presence of persistent infections such 
as HIV as well as TB. As discussed in section 1.2.4, two such markers of exhaustion 
we will discuss is programmed death – 1 (PD-1) and T-cell immunoglobulin mucin 
domain - 3 (TIM-3) that plays a role in regulating T cell immunity and cell tolerance 
(Sakhdari et al., 2012). 
 
1.2.5.1 PD-1 inhibition marker 
PD-1 is expressed on activated T-cells such as CD4
+ 
and CD8
+
, NK cells, B cells 
and monocytes. When PD-1 binds to its ligands PD-1/L1 and PD-1/L2 which is 
expressed on dendritic cells, it inhibits T-cell activation and induces T-cell exhaustion 
(Larsson et al., 2013)(Tousif et al., 2011). This PD-1/PD-L interaction will only occur 
at the same time as the TCR/MHC II interaction takes place. Studies have shown 
that  in CD8
+
T-cells, the PD-1 expression is directly proportional to HIV disease 
severity such as increased viral load and decreased CD4
+ 
T-cell count (Larsson et 
al., 2013).     
Furthermore, Jurado et al. corroborate that the  prevention of PD-1 and its ligands is 
associated with the inhibition of T-cell effector functions in active TB due to  
increased IFN-γ producing lymphocytes, needed for protective immunity against TB 
(Jurado et al., 2008) 
 
1.2.5.2 TIM-3 inhibitory molecule 
TIM3 is a molecule expressed on IFN-γ Th1 cells, but not on Th2 cells and plays a 
role in regulating Th1 immunity and tolerance by negatively regulating IFN-γ 
secretion by inducing cell death when binding to its ligand Galectin–9 (Hastings et al. 
2009). This indicates the inhibitory role of TIM-3 on CD4
+
T-cells(Wang et al., 2011). 
Furthermore, TIM-3 is  also expressed on HIV specific T-cells undergoing exhaustion 
that produce little to no cytokines (Jones et al., 2008). 
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TIM-3
+
CD4
+
T-cells produce Th1/Th22 cytokines and limit intracellular replication of 
the M.tb bacilli in macrophages. In active TB, TIM-3 expressing CD4
+
T-cells 
displayed polarized effector memory phenotypes lacking CD27 (Qiu et al., 2012). 
TIM-3 is also a negative regulator of Th1 and Th17 cytokines in T-cells, as IFN-γ  
production is increased when the TIM-3 pathway is blocked, but does not have an 
overall effect on cytokine production in the body (Hastings et al., 2009). 
 
1.2.6 CD27 and CD45RO memory markers 
Once T-cells are released from the thymus it undergoes different stages of 
differentiation, and the CD45 antigen isoforms best discriminates between primed 
and unprimedT-cells. CD45RA is expressed on naïve T-cells, whereas CD45RO is a 
marker of memory T-cells(Schiött, Lindstedt, Johansson-Lindbom, Roggen, & 
Borrebaeck, 2004). CD27 is a member of the tumor necrosis factor receptor family 
(TNFR) which further delineates the different stages of T-cell differentiation. CD27 
has a co-stimulatory function, and after initial up-regulation upon T-cell receptor 
engagement, CD27 expression is gradually irreversibly down regulated following 
repeated antigenic stimulation (Fritsch et al., 2005). Therefore CD4
+
CD45RO
+
 
memory T-cells, can further be divided into two subsets based on their CD27 
expression (Schiött et al., 2004). The T-cell path of differentiation can best be 
described as follows: naïve T-cells (TN) - CD45RO
-
CD27
+
, that progress into central 
memory T-cells (TCM) – CD45RO
+
CD27
+ 
 which in turn progress into  effector 
memory cells (TEM) – CD45RO
+
CD27
+
 and with persistent antigenic stimulation 
become CD45RO
+
CD27
-
 and then finally to the terminally differentiated effector 
memory  T-cells (TDEM) with the phenotype CD45RO
-
CD27
-
(Schiött et al., 
2004;Rovina et al., 2013). The sequence of events described above is tabulated in 
table 1.3 below, and shows the role of the CD4 subsets in the diagnosis of active vs. 
latent TB disease. Effector memory cells secrete effector cytokines and have a 
strong antigen recall response, whereas central memory cells require co-stimulation 
and lack responsiveness toward antigen and T-cell receptor triggering. Rovina et al. 
2013 has shown that TDEM cells, lacking CD27 and expressing IFN-γ is an accurate 
discriminator between active and latent TB disease.  Therefore including CD27 and 
CD45RO in our flow cytometry panel, will assist in distinguishing stages of immune 
Stellenbosch University  https://scholar.sun.ac.za
  
23 
 
activation according to T-cell memory phenotype and subsequently assist in 
determining the disease state.   
 
Table 1.3Cytokine expression profiles within the different T-cell subsets 
T – cell subset Expression profile Disease state indicated 
Naive T-cells CD45RO- CD27+  
Active disease 
Central memory CD45RO+ CD27+ 
Effector memory CD45RO+ CD27-  
Latent disease/BCG vaccine 
Terminally differentiated 
effector memory 
CD45RO- CD27- 
 
 
1.2.7 IFN-γ and TNF-α cytokines 
Protective immunity against TB is crucial and T-cell mediated immune responses 
play a critical role in controlling M.tb infection. IFN-γ released by CD4+T-cells 
activate phagocytes to incorporate the intracellular pathogen and this provides the 
host with protection against disease (Walzl et al., 2011). Likewise, TNF-α assists in 
cell apoptosis, cell activation, recruitment and differentiation and these functions 
make TNF-α pivotal in sustaining protective immune responses in TB (Mootoo et 
al.,2009). According to Walzl et al. 2011 specific cytokine expression profiles of 
CD4
+ 
T-cells are associated with bacterial loads at the various stages of TB disease 
(Walzl et al., 2011). Furthermore Pollock et al. 2013 has found that CD4
+
T-cells that 
are bi-functional secreting IFN-γ/TNF-α or IFN-γ only or TNF-α only were indicative 
of active TB disease. On the other hand, cells with an effector phenotype secreting 
TNF-α only was an accurate marker to distinguish between active and latent 
infection and studies done by Harari et al. 2011 confirmed this. Likewise, a study 
done by Rovina et al. 2013 corroborate these findings and further demonstrated, 
along with Rueda et al. 2010 that CD4
+
T-cells expressing IFN-γ and lack CD27, is an 
accurate indicator of LTBI. 
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1.3 Whole blood vs. PBMC’s 
In order to measure immune responses in T-cells, either whole blood or peripheral 
blood mononuclear cells (PBMC’s) can be used to stimulate the T-cells. However 
depending on the assay requirements, normally a large volume of whole blood is 
required if PBMC isolations is needed, which in itself is time consuming and 
laborious.  This studying of human T – cell immunity becomes even more 
challenging even in optimal conditions, especially in children and infants when the 
volume of blood for assays is limited (Hanekom et al. 2004). Based on this 
observations, Hanekom et al. (2004) investigated a flow cytometry intracellular 
cytokine assay utilizing whole blood as the specimen of choice because volumes as 
little as 200µl of whole blood was sufficient.  Similarly, Bourguignon and colleagues 
agreed with the previous author and further stated that another disadvantage of 
using PBMC’s was the need for liquid nitrogen for the cryopreservation of cells and 
this may be troublesome in some resource constraint areas (Bourguignon et al., 
2014). 
The flow cytometry intracellular cytokine assay backgrounds was studied in both 
whole blood and PBMC’s and results indicated that background IFN-y expression 
was considerably less in whole blood samples compared to PBMC (Figure 1.6) 
(Hanekom et al., 2004). Despite the low IFN-y expression in whole blood, compared 
to PBMC’s, others continue the investigation of intracellular cytokine expression in 
whole blood. 
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Figure 1.6 IFN-γ background expression. Background expression of IFN-y released by CD4
+
 T-
cells following the incubation of whole blood (black bars) and of freshly isolated PBMC (grey bars) 
samples of four patients. (Hanekom et al., 2004) 
 
 
Likewise, Nomura and colleagues also noted that whole blood offers a more 
physiological environment and this may enhance the T-cell response following 
antigenic stimulation (Nomura et al., 2000). Whole blood not only preserves natural 
cell – cell interactions and soluble factors that play a role in cell activation, but also 
provides more representative in-vivo conditions than the alternate PBMC method 
(Crucian & Sams, 2001). 
 
Thus for the purpose of our study, whole blood is the specimen of choice and is used 
for optimization purposes as this technique is simple, avoids time-consuming 
separation steps and is performed in an environment close to in vivo. 
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1.4The present study 
From the abovementioned literature review and the growing statistics of TB/HIV-1 
co-infection, early and accurate identification of both active and LTBI and effective 
treatment of active TB is imperative. It is evident that there is a need for new specific 
TB diagnostic tests. 
In this present study we aim to aid in the diagnosis and distinguish between BCG 
vaccine and TB disease in peripheral blood using flow cytometry by generating TB-
specific intracellular cytokine (TNF-α and/or IFN-ү) profiles of CD4+ T-cell 
populations following exposure to TB specific antigens. 
Whole blood and not peripheral blood mononuclear cells (PBMC’s) is used for 
optimization purposes as this technique is simple, avoids time-consuming separation 
steps and is performed in an environment close to in vivo. 
Thus the objective of the present study is to optimise the experimental conditions 
(i.e. antibody volumes and intracellular staining protocols) for this assay prior patient 
analysis. 
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For optimisation purposes only 18 TB positive (6 – HIV+ and 12 HIV-) patients as well 
as 10 TB negative and HIV negative along with the appropriate negative 
(unstimulated) and positive assay controls (SEB) were tested and analysed using 
flow cytometry to establish a foundation for comparisons.  
The samples were tested for the release of TNF-α and IFN-γ (positivity in stimulated 
CD4
+
T-cells) in terms of mean fluorescence intensity (MFI). We will also compare 
the cytokine expression profiles of healthy controls selected to that of newly 
diagnosed TB cases, before initiation of treatment and compare the results thereof 
with the gold standard methods to determine assay sensitivity and specificity. If 
established this technique will potentially enable diagnosticians to distinguish BCG 
vaccine and TB disease (latent or active). 
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Chapter 2 – Materials and Methods 
 
2.1 Study cohort/design and Ethical considerations 
The present study forms part of a larger study of which ethical approval has been 
given by the Health Research Ethics Committee (HREC), Faculty of Medicine and 
Health Sciences (FMHS) at Stellenbosch University - N11/08/246. Further 
permission to conduct this study was also obtained from the Western Cape 
Government, Department of Health (DOH) in order to recruit patients from Tygerberg 
Hospital (TBH). This study forms part of a larger study which focuses on the 
establishment of a flow cytometry-based TB assay and the validation and 
implementation of the assay in a clinical set up. However, for the purpose of this 
study we focus on the optimisation and development of this flow cytometry-based 
assay.  
Eighteen consenting, previously confirmed HIV
neg
TB
pos
, patients were recruited from 
TBH while 10 HIV
neg
TB
neg
 consenting participants which served as the negative 
control group were recruited from the Division of Haematology, Tygerberg Hospital.  
HIV diagnostic confirmation of participating patients were screened in the NHLS, 
Division of Virology Unit, using the HIV p24 Antigen ELISA assay, while a positive 
TB diagnosis was confirmed in the Division of Medical Microbiology on the Cepheid 
Gene Xpert® (Sunnyvale, CA, USA). For the control group participation, their TB 
negative status was confirmed based on the completion of a quarterly TB 
questionnaire used to screen NHLS staff members. In addition, HIV p24 Antigen 
ELISA tests were also performed to confirm HIV status.  
 
2.1.1 Inclusion criteria 
Patients older than 18 years, who are treatment naïve, HIV negative and TB positive 
were included.  
2.1.2 Exclusion criteria 
HIV positive patients with a CD4 count below 350 cells/mm
3 
and patients who have 
previously been confirmed as having MDR/XDR TB have been excluded. In addition, 
patients who have commenced empiric TB treatment were also excluded from this 
study. 
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2.2 Principle of tests 
2.2.1 HIV Ag/Ab Combo for HIV screening/confirmation 
The Architect HIV Ag/Ab Combo assay (Vironostika, BioMerieux, The Netherlands),  
is a two-step chemiluminescent microparticle immunoassay (CMIA) which 
qualitatively detects HIV p24 antigen and antibodies to HIV type 1 and/or type 2 in 
human serum or plasma. Firstly, the patient’s serum, Architect wash buffer, assay 
diluent and paramagnetic microparticles were all combined. The HIV p24 antigen 
and HIV-1/HIV-2 antibodies present in the serum bind to the HIV-1/HIV-2 antigen 
and HIV p24 monoclonal (mouse) antibody coated microparticles. Following a wash 
step, the HIV p24 antigen and HIV-1/HIV-2 antibodies bind to the acridinium – 
labelled conjugates consisting of HIV-1/HIV2 antigens (recombinant), synthetic 
peptides and HIV p24 antibody (mouse monoclonal). After a consecutive wash cycle, 
pre-trigger (1.32% [w/v] hydrogen peroxide) and trigger (0.35N sodium hydroxide) 
solutions were added to the reaction mixture and the resulting chemiluminescent 
reaction was measured as relative light units (RLUs). The amount of HIV antigens 
and antibodies in the sample is directly proportional to the RLUs detected by the 
system optics. A positive result was recorded when a sample had a signal to cut off 
(S/CO) >1.00 and a non-reactive sample had a S/CO <1.00. The cut off signal was 
determined from the Architect HIV Ag/Ab Combo calibration. 
 
2.3 Sample Collection and processing 
Following consent, 6ml of peripheral blood was collected by venepuncture into 6ml 
Sodium Heparin BD Vacutainer tubes (BD Vacutainer, San Jose, CA). Samples were 
transported at room temperature from the clinic to Tygerberg Haematology 
laboratory, within 6 hours of collection. 
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2.4 Optimization of experimental conditions 
Briefly, the following steps will be followed in order optimize the experimental 
conditions for this assay:  
i) Cell stimulation in the presence or absence of antigens such as early secretory 
antigenic target-6 (ESAT-6), culture filtrate protein-10 (CFP-10) and Staphylococcus 
Enterotoxin B (SEB)  
ii) Cytokine accumulation,  
iii) Fixation, 
iv) Permeabilization and 
v) Flow cytometry.  
 
2.4.1. Baseline intracellular marker protocol 
Intracellular and cell surface expression of T-cell markers was determined by 
staining cells with fluorochrome labelled monoclonal antibodies. Lineage markers 
anti-CD45 ECD (J33 clone), anti-CD3 PC5 (UCHT 1 clone) and anti-CD4 APC 
(13B8.2 clone) from Beckman coulter, Inc., USA, were used to characterize T-cells. 
Antibodies were combined to form a cocktail as shown in Table 2.1 along with 
supplier details. 
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Table 2.1 Antibody cocktail for surface markers. 
 
Antibody Volume Function Supplier 
CD45-ECD 8µl   Pan-leucocyte marker Beckman coulter, 
Inc, USA 
CD3-PC5 2µl   T cell receptor Beckman coulter, 
Inc, USA 
CD4-APC 6µl   Lineage marker Beckman coulter, 
Inc, USA 
CD27-APC 750 4µl   T cell memory marker Beckman coulter, 
Inc, USA 
TIM3-PC7 4µl   Marker of T cell 
exhaustion 
BD Biosciences, 
San Diego, CA, 
USA 
CD45RO – BO 3µl  T cell memory marker BD Biosciences, 
San Diego, CA, 
USA 
Total 27µl of cocktail to be 
added to each 50ul 
aliquot of whole blood. 
  
Abbreviations: APC- Allophycocyanin, APC 750- Allophycocyanin-Alexa Fluor 750, BO- Brilliant 
Orange, ECD- Phycoerythrin-Texas Red, PC5- PhycoerythrinCyanin 5, PC7- PhycoerythrinCyanin 7 
 
 
The sample preparation procedure for flow cytometry analyses is further 
demonstrated in Figure 2.1.  Briefly, whole blood was divided into three aliquots of 
200µl each in 5ml FACS Tubes (BD Falcon, BD Biosciences, MA, USA) in order to 
represent the un-stimulated (negative control tube), one representing and containing 
ESAT6/CFP10 antigens and another one representing the positive control, 
containing the SEB antigen. Antigens were added to the respective tubes and a co-
stimulant anti – CD28 (Beckman coulter, Inc., USA) needed for T-cell activation was 
also added to all three representative tubes. After the addition of the antigens to the 
respective tubes, the three samples were incubated at 37°C for 2 hours, after which 
5µl of 5µg/ml Golgi transport inhibitor Brefeldin A was added and samples were 
further incubated overnight for 18 hours.  
After incubation, samples were removed and stained with 1µl Fixable Viability Dye 
eFluor® 455UV purchased from eBioscience(San Diego, CA, USA) and incubated at 
room temperature (RT) for 30min. 
 
For each of the three samples a secondary tube was labelled, however the 
unstimulated sample received an additional tube and this will serve as the 
unstimulated/unstained control as this tube will receive no monoclonal 
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antibodies.Following cell stimulation and cytokine accumulation, 50µl from the 
primary tubes containing the stimulated and un-stimulated whole blood as is the 
case with the negative control, was pipetted into the four secondary tubes 
respectively.  Twenty seven microliters of the surface marker antibody cocktail as 
shown in Table 2.1 was added to each of the three representative tubes. The 
unstimulated/unstained tube received no antibody as this will serve as the 
unstimulated, unstained control which is used to verify autofluorescence.  All 
samples were incubated for 15 – 20min in the dark at RT. 
 
Following surface marker antibody incubation, the Beckman Coulter PerFix-nc Kit 
(no centrifuge assay Kit) was used to fix and permeabilize cells. Five microlitres of 
Buffer 1 (fixative reagent) was added to each representative tube. The tubes were 
vortexed and incubated in the dark at RT for 15min. After incubation, samples were 
vortexed again and 300µl of Buffer 2 (permeabilizing reagent) was added and 
samples were vortexed immediately. Intracellular markers Fluorescein 
isothiocyanate (FITC) labelled IFN-γ (18µl) and Phycoerythrin (PE) labelled TNF-α 
(14µl) (volumes determined from optimisation) both from Beckman coulter, Inc., 
USA, was added, vortexed and placed in the dark to incubate for 15 – 30min at RT. 
Lastly, 400µl of the Final 1X Reagent (prepared from the 10x concentrated Final 
Solution) was added to all four tubes and samples were acquired on the NAVIOS.  
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Figure 2.1: A schematic diagram of sample preparation for flow cytometry analysis 
  
 
   
 
 
Stimulate 200µl WB with TB antigens ESAT6/CFP10 and SEB (positive control) in 5ml FACS tubes 
For each tube label a secondary tube and pipette 50µl WB in each. For the negative control prepare two tubes 
with 50µl WB in each – one will serve as an unstained control 
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2.5 Instrument quality control and compensation 
Various steps were taken to ensure that the instrument operates optimally on a daily 
basis. Before analysing patient samples, the following steps were taken: 
 
2.5.1 Voltage Settings 
Voltages were set on an unstained control by adjusting the voltage of each 
photomultiplier tube (PMT) to bring the population onto scale. Following this, single 
stained controls were then run on the instrument to further adjust the voltage for 
each PMT. Furthermore, compensation was performed as explained below and the 
voltages were verified on the final verification tube. 
 
2.5.2 Compensation 
In flow cytometry, spectral overlap occurs when the fluorescence of one 
fluorochrome e.g. PE, is picked up by another detector e.g. the FITC detector. This 
happens when the spectral emission of certain fluorochromes overlap. 
Compensation was therefore performed to adjust for spectral overlap between the 
fluorochromes and this was done according to the Beckman Coulter specifications. 
Briefly, 50µl whole blood was added to a 5ml Falcon
TM
 tube, followed by the titrated 
amount of antibody and the tube is then placed in the Beckman Coulter  TQ-prep 
instrument. Compensation was then performed on the Beckman Coulter Navios 
instrument using the automated procedure and those settings was then analysed 
using the Beckman Coulter Kaluza software. Some antibodies in the panel did not 
have clear separation of their negative and positive populations, and in these 
instances we used different antibodies for the same fluorochrome. Table 2.2 
describes this. Compensation was only re-run after the instrument was serviced or if 
the daily QC failed repeatedly despite following troubleshooting steps. 
  
Stellenbosch University  https://scholar.sun.ac.za
  
35 
 
Table 2.2 Antibody panel used for project compared to compensation antibody panel 
Flow cytometry project antibody panel 
FL1 
FITC 
FL2 
PE 
FL3 
ECD 
FL4 
PC-5 
FL5 
PC-7 
FL6 
APC 
FL7 
ALEXA
700 
FL8 
APC-750 
F9 
450/50 
F10 
BO 
IFN-γ* TNF-α* CD45 CD3 TIM3 CD4 N/A CD27 Viability  CD45RO 
Flow cytometry compensation panel  
FL1 
FITC 
FL2 
PE 
FL3 
ECD 
FL4 
PC-5 
FL5 
PC-7 
FL6 
APC 
F7 
ALEXA
700 
F8 
APC-750 
F9 
450/50 
F10 
BO 
CD45RA* CD45RO* CD45 CD3 CD3 CD4 N/A CD27 CD45-PB CD45RO 
*Denotes intracellular markers; Abbreviations: PB – Pacific Blue 
 
2.5.3 Daily QC 
Quality control checks were done every day upon start-up of the instrument. 
Beckman Coulter Flowcheck Pro fluorospheres were used to assess the stability of 
the laminar flow (fluidics), and the detector voltages of the instrument. Furthermore, 
the instrument monitors its performance over time and plots these details on a 
Levey-Jennings chart. Through this we were able to see if the detector’s 
performance is out of range and perform the necessary corrective action. 
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Volume 
(ul) 
2.6 Assay Optimization 
Assay optimisation forms the foundation of the intracellular staining protocol. 
Optimisation was divided into (i) surface and intracellular monoclonal antibody 
volume (ii) Overnight Incubation temperature at 37°C or 4°C and (iii) staining with 
surface markers before permeabilizing cells.  
 
2.6.1 Monoclonal antibody optimisation 
In order to use fewer antibody volumes as a way of saving cost, an antibody titration 
is performed. The optimal antibody volume will result in the highest signal of the 
positive population and the lowest signal of the negative population. The signal to 
noise ratio (S:N) = D, is used to quantitatively determine expression of cell 
separation when the positive and negative populations can clearly be distinguished 
from each other as seen in figure 2.2 A.  
 
 
 
 
 
Figure 2.2 Monoclonal Antibody optimisation. Adapted from (Lamoreaux, Roederer, & Koup, 
2006) *MFI – Mean fluorescent Intensity 
A Signal to noise ratio is 
calculated by dividing the MFI 
of the positive population (red) 
by the MFI of the negative 
population (black).  
B Saturation point on curve 
indicating the volume of 
antibody that results in the 
least amount of background 
fluorescence  
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This is calculated by dividing the mean fluorescence intensity (MFI) of the positive 
population by the MFI of the negative population. Background noise can be kept to a 
minimum when small antibody volumes can be used in samples with high cell 
concentrations (Hulspas, O’Gorman, Wood, Gratama, & Robert Sutherland, 2009). 
Together with the S:N, the optimal volume was established from the plateau area 
(saturation point) of the antibody titration curve as demonstrated in figure 2.2B, 
however, statistical criteria was used as confirmation (Collino, Jaldin-Fincati, & 
Chiabrando, 2007). Optimizing the antibody volume determines the maximum 
amount of antibody that results in the least background fluorescence and this is 
achieved by focusing on the fluorescence intensity of the negative population rather 
than the difference between the two populations (Hulspas, 2010).  
Briefly, 50µl whole blood (WB) was stained with decreasing volumes of surface 
markers CD4–APC, CD45-ECD, CD3-PC5, TIM3-PC7, CD27-APC 750 and 
CD45RO-Brilliant Orange as listed in table 2.1. Where the manufacturer’s suggested 
volume was 20µl, antibodies were added as follows: 20µl, 18µl, 16µl, 14µl, 12µl, 
10µl, 8µl and 6µl. Where the recommended volume was 10µl, antibodies were added 
as follows: 10µl, 8µl, 6µl, 4µl, 2µl and 1µl. Tubes were placed in the Beckman 
Coulter TQ-Prep, where it was incubated and lysed. Each tube was then run in 
triplicate on the Beckman Coulter, NAVIOS flow cytometer. The optimal volume was 
determined following visual analysis of density plots, S:N and statistical criteria (data 
shown in Chapter 3). 
For the intracellular markers, the baseline protocol as described above was followed.  
TNFα-PE and IFNγ-FITC was added in decreasing volumes starting at 20µl down to 
6µl. Samples were then fixed and acquired on the NAVIOS in triplicate. The optimal 
volume of these intracellular markers was determined following visual analysis of 
density plots, S:N and statistical criteria.  
 
2.6.2 Overnight Incubation with Brefeldin A -  37°C vs. 4°C 
In order to determine whether an incubation temperature of 37°C and/or 4°C will 
have a difference on experimental conditions, both of these temperatures were 
tested to determine its effects. Two samples of 500µl WB each was stimulated with 
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1µg/ml SEB and 1µg/ml CD28. Both samples were then incubated at 37°C for 2 
hours in an incubator, however; one of the samples was placed in a beaker of water 
in the incubator. Five micrograms per millilitre of BFA was added to both samples. 
The sample with the beaker of water was then placed in the refrigerator at 4°C 
overnight (18 hours) – this was done to maintain a steady decrease in the incubation 
temperature, and the other sample remained incubated at 37°C. The following day 
both samples were stained with lineage markers CD45-ECD, CD4-APC and CD3-
PC5 as well as a viability marker 7-AAD (Beckman coulter, Inc., USA). Samples 
were then placed in the TQ-Prep after which it was acquired on the Beckman Coulter 
NAVIOS flow cytometer.  
 
2.6.3 Staining with surface markers before or after permeabilizing cells 
Previous protocols suggest staining of surface markers after fixation and 
permeabilization of cells, however following this route did not yield any CD4
+
 T-cells. 
We experimented with staining stimulated cells before and after fixation, as 
Lamoreaux et al., 2006 has stated that the fixative can change the epitope and 
subsequently the avidity of the antibody-antigen reaction. We followed the same 
stimulation protocol as before, except in this experiment, cells were stained with 
CD4-APC before fixing and permeabilization. See Chapter 3 for results.  
 
2.7 Flow cytometry gating strategy 
Flow cytometric acquisition was performed on a ten colour Beckman Coulter Navios, 
while data analyses was performed using Kaluza software (Beckman Coulter). A 
density plot of forward scatter (FS) peak vs. FS integral was drawn and a gate was 
set around the single cells. These cells were then interrogated on a density plot of 
side scatter (SS) vs. Viability marker – pacific blue to separate viable cells from dead 
cells. The viable cells were used in a secondary plot of SS vs. CD45-ECD to put a 
gate around the lymphocyte population. The lymphocyte population was separated 
into T-cells and B-cells using a density plot of CD3-PC5 vs. CD45-ECD. The T-cell 
population of cells was further interrogated and a density plot of CD3-PC5 vs. CD4-
APC was drawn and a gate was set around the CD4 population of cells. This CD4 
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population of cells was further delineated into the respective CD4
+
 T-cell subsets – 
data shown in Chapter 3.  A detailed gating strategy can be seen in figure 2.3.This 
gating strategy will be applied to all samples for analyses. 
 
 
Figure 2.3A detailed sequential gating strategy. (A) Forward Scatter (FS) peak vs. FS integral 
shows doublet discrimination and a gate is drawn around the single cells. (B) Side scatter (SS) vs. 
Viability marker, gated on single cells, was used to gate on viable cells. (C) SS vs. CD45-ECD gated 
on viable cells and a gate was placed around lymphocyte population. (D) A secondary plot of CD3-
PC5 vs. CD45-ECD gated on the lymphocyte population was drawn to separate T-cells from B-cells 
(E) CD4 cells were isolated using CD3-PC5 vs. CD4-APC on density plot gated on the T-cell 
population.  
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2.8 Statistics 
Box-and-whisker plots were used to present the data and have the following format: 
the median value is represented by a horizontal line in the box; the box represents 
the interquartile range (25-75 percentile) of the data, while the whiskers indicate the 
minimum and maximum values. When comparing two variables, an unpaired T-test 
was used when the data was normally distributed, while a Mann-Whitney U test was 
performed for non-parametric data. The repeated measures one-way Analysis of 
Variance (ANOVA) was used for comparing multiple factors e.g. IFN-γ expression 
across the CD4
+
 T-cell subsets within the patient group. This was followed by a 
Dunn’s multiple comparison post-test for non-parametric data. Data is reported as 
median percentage expression ± standard deviation (SD), with p<0.05 indicating 
significant results and results with a p value >0.05 was considered not-significant 
(NS). A statistician from the Stellenbosch University, Centre for Evidence Based 
Health Care, Biostatistics Unit was consulted and it was determined that a minimum 
of 8 subjects per group was needed for statistical power and to verify that all 
statistical analyses done were correct for that data set. GraphPad Prism software v.5 
(GraphPad Software, San Diego CA, www.graphpad.com) was used for all statistical 
analyses 
 
2.9 Overview of data analysis 
As mentioned above, an overview of the optimization results will be given first in 
figure 2.4 in order to introduce the different cytokine profile result comparisons within 
the different subpopulations analysed. Following optimization, patients analysis was 
performed by comparing statistical analyses of baseline cytokine (IFN-y, and TNF-α), 
and TIM-3 expression between TB-positive patients and controls upon stimulation 
with TB antigens ESAT6 & CFP10 (E/C), SEB (positive assay control) as well as an 
unstimulated baseline (negative control).  
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Figure 2.4 Schematic overview of data analysis.  Results were divided into study subjects and 
healthy controls. Each of these groups was further subdivided into baseline (negative control), E/C 
test condition and SEB (positive control). All results were compared. 
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Chapter 3 – Results 
 
3.1 Demographics of study participants 
A total of 18 patients were recruited for this study, which included either mixed race 
or black patients. The mean age (years) of this group was 39.11(Range: 18 – 63). 
The control group consisted of 10 participants aged between 27 and 40 years of age, 
and had a mean age of 30. The dominant gender was males with 66.67% in the 
study group and in the control group females were in the majority with 60%. Table 
3.1 below summarises the patient demographics. For data analyses, the patient 
group was combined and analysed as a whole. 
 
Table 3.1 Demographics of study participants 
Parameter 
 
TB+HIV- 
 
TB+HIV+ 
 
Control group 
 
No. of Participants 12 6 10 
Age range 18 – 63 36 – 58 25– 40 
Age (mean years) 37.58 42.16 31.9 
% of females 33.33 33.33 60 
% of males 66.66 66.66 40 
% mixed race 58.33 41.66 70 
% black 83.33 16.66 30 
 
 
3.2 AssayOptimisation 
3.2.1 Incubation temperature 
In order to determine the effect of incubation temperature on the CD4
+ 
T-cell yield 
and experimental conditions, two samples of 500µl WB each were incubated 
overnight at 4°C and 37°C respectively. Results in figure 3.1 below showed no 
statistical difference between incubation at 37°C vs. 4°C and in conclusion, samples 
were incubated at 37°C overnight for all other subsequent incubations. 
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Figure 3.1 Relative percentage (%) CD4
+
 T-cells per stimulation condition. Incubation of samples 
at 4°C vs. 37°C. Graph shows no significant difference between the two incubation temperatures. This 
concludes that samples can be incubated at 37°C. [     4°C;      37°C]  
 
 
3.2.2 Staining with surface markers before or after permeabilizing cells 
The intracellular staining kit (PerFixnc, Beckman Coulter,USA) used in this study 
suggested staining cells with surface markers after permeabilizing cells; however we 
were unable to detect any CD4
+
 T-cells, most likely due to antigen loss after fixation. 
We thus stained cells with surface markers before permeabilizing and fixing cells and 
this yielded a CD4
+ 
T-cell population, clearly distinguished from the negative cells as 
seen in figure 3.2 below.As staining of surface marker before permeabilization and 
fixation was proven to yield the best result, the workflow in the protocol/experimental 
conditionswas modified for all subsequent staining of other surface markers.  
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Figure 3.2:The effect of staining with surface markers before and after permeabilizing and 
fixation. (A) Baseline (unstained) control for surface marker CD4 – APC antibody. (B) Cells stained 
with surface marker, CD4-APC after fixing and permeabilizing. Histogram plot shows no significant 
increase in MFI of a population within the positive region. (C) Cells stained with surface marker, CD4-
APC before fixation, histogram shows an increase in MFI of the positive population and clear 
separation from the negative population. This concludes that fixative has an effect on the cell sur face 
epitope, and samples should be stained with surface markers before fixing of cells. * APC - 
Allophycocyanin 
 
3.2.3 Antibody titrations 
Antibodies were titrated to determine the optimal volume required for the staining 
protocol to avoid under- or over staining of the cells but also from a cost perspective, 
The optimal antibody volume was determined using: statistical analyses, visual 
analyses and signal-to-noise(S:N) ratio, all of which are detailed below. For the 
purposes of this section, CD3-PC5 is being used as an example. Statistics for the 
remaining fluorochromes can be found in Addendum 1. 
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3.2.3.1 Statistical determination of optimal antibody volumes 
The unpaired t-test was used to determine statistical differences in the MFI of the 
various volumes used. Table 3.2 shows CD3-PC5 as an example (see Addendum 1 
for complete antibody list). Rows 1-3 show a significant difference in MFI (p=0.0253, 
p=0.0129, and p=0.0006 respectively), suggesting that these volumes cannot be 
used for optimal staining. 
 
Table 3.2 Statistical determination of optimal antibody volume 
#  Antibody  Comparison (µl)  MFI mean difference P value 
1  CD3-PC5  1 vs. 2  -64.22 0.0253 * 
2    2 vs. 4  -41.26 0.0129 * 
3    4 vs. 6  -26.22 0.0006 *** 
4    6 vs. 8  2.01 0.4387 (NS) 
5    8 vs. 10  -1.99 0.1022 (NS) 
µl – microlitres, NS – not significant, MFI – mean fluorescence intensity, PC5 - Phycoerythrin-
Cyanin5.1, * - p<0.05, ** - p<0.01, *** p<0.001 
 
The results detailed in Table 3.2 are plotted on a graph as seen in Figure 3.3 and 
shows the antibody titration curve for CD3-PC5. The saturation point on the graph is 
reached at 6µl (indicated by red dot) which has a mean percentage positive-staining 
cells of 99.35% and the MFI = 119.04. This confirms the statistical analyses that 
showed no significant difference between 6µl and 8µl of antibody. Although we can 
take 6µl as the optimal volume based on the statistics, we still have to interpret these 
results together with the visual analyses and S:N ratio. 
 
 
Figure 3.3 Determination of optimal antibody volume using the MFI. The red dot indicates the 
saturation point at 6µl. Since there is no statistical difference between 6µl and 8µl - 6µl would the 
volume to use. *MFI – mean fluorescent intensity 
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3.2.3.2 Visual analyses of optimal antibody volume 
The maximum amount of antibody required, which resulted in the lowest background 
fluorescence (or “noise”), was determined by comparing the density plots of the 
different volumes of antibody. Figure 3.4 below shows the dot plots of all volumes for 
visual analyses. The dot plots show clear separation of the negative and positive 
populations for each volume of antibody. However, 1µl and 2µl (within the red 
square) are the only two plots with a negative population closest to that of the 
unstained control. This indicates that these two volumes will give the least amount of 
background fluorescence and the S:N ratio will be able to determine which of the two 
volumes will work best. 
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Figure 3.4 Determining the minimum amount of antibody to use. The graphs show antibody on 
the y-axis vs. Side Scatter on the x-axis. The unstained control is used to set the cut-off for the 
negative region.  All plots show clear separation of the negative and positive populations. The plots 
within the red square have a portion of their negative populations within the negative region, closest to 
that of the unstained control and would be the volumes of choice, however these results have to be 
read together with the S:N ratio. *µl – microliters; PC5 – Phycoerythrin-Cyanin 5.1; SS INT – side 
scatter integrel 
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3.2.3.3 Determination of optimal antibody volume using the S:N ratio 
The histogram plots below in figure 3.5 show the separation of the negative and 
positive populations. The geometric mean is used to determine the MFI for each 
population and these values were used to calculate the S:N ratio for each volume.  
 
Figure 3.5 Histogram plots for antibody CD3-PC5. The positive MFI is determined from the 
geometric mean of the positive population and the negative MFI is determined from the geometric 
mean of the negative population. *PC5 – Phycoerythrin-Cyanin 5.1 
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The S:N ratio was calculated by dividing the MFI of the positive population by the 
MFI of the negative population for each antibody volume. The volume with the 
highest S:N ratio is the volume that will result in maximum staining of the cells with 
the least amount of background noise. Table 3.3 below shows the S:N ratio results 
for the antibody CD3-PC5. Based on the S:N ratio it is determined that 2µl is the 
optimal volume of CD3-PC5 to be used. See Addendum 2 for complete antibody list. 
 
Table 3.3 Determination of optimal antibody volume using the S:N ratio 
Antibody  Volume (µl)  S:N ratio  MFI of negative 
population 
 
 
MFI of positive 
population 
CD3  1  56.31  1.23  69.27 
  2  80.67  1.37  110.53 
  4  71.45  1.46  104.32 
  6  73.48  1.62  119.04 
  8  79.03  1.63  128.82 
  10  91.89  1.48  136.01 
µl – microliter, S:N – signal to noise ratio, MFI – mean fluorescence intensity 
 
Taking all three criteria into consideration i) statistical analyses ii) visual analysis and 
iii) S:N ratio we have concluded that 2µl is the volume of choice that will give us 
maximum staining of cells with the least amount of non-specific binding. The 
statistical analysis indicated 6µl as the volume to be used; however, visually 6µl had 
both its negative and positive populations within the positive region, indicating a high 
degree of non-specific binding. Visually, 1µl and 2µl were the two volumes that had 
some portion of their negative population within the set negative region meaning one 
of these two volumes could be used. The third criteria determined that 2µl had the 
highest S:N ratio, hence in conclusion we used 2µl of CD3 – PC5. This same 
strategy was applied to all surface and intracellular antibodies.   
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3.3 CD4
+
 T cell subset distribution 
CD4
+ 
T-cell population was further delineated into its respective sub populations 
based on their CD27 and CD45RO expression. Figure 3.6 below shows the different 
populations i.e. naïve cells, central memory, effector memory and terminally 
differentiated T cells. Polarisation towards a specific subset may indicate disease 
status, e.g. active disease will stimulate expansion of effector memory cells 
(Jasenosky et al., 2015). 
 
 
Figure 3.6 CD4
+
 T-cell subsets. CD4
+ 
T cells are further delineated into different subsets based on 
their CD45RO and CD27 positivity. * APC750 - Allophycocyanin 
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Table 3.4 below shows the percentage expression of each cell type in the control vs. 
patient groups. Naïve cells (CD45RO
-
CD27
+
) were the most abundant cell type in 
both groups and compared to each other they were not significantly different. The 
differences in expression between the two groups for all cell types were not 
significant.  
 
Table 3.4 Percentage positivity of CD4
+
 T-cell subset cell expression. 
p–value> 0.05 = Not significant (NS) 
  
 Cell phenotype Healthy controls TB Patients p-value 
Naïve cells (TN) CD45RO
-CD27+ 37.11 ± 14.22 47.48 ± 20.96 NS 
Central memory(TCM) CD45RO
+CD27+ 19.10 ± 10.79 11.51 ± 8.62 NS 
Effector memory(TEM) CD45RO
+CD27- 23.85 ± 19.96 21.92 ± 13.25 NS 
Terminally differentiated 
effector memory (TDEM) 
CD45RO-CD27- 7.575 ± 9.99 13.02 ± 20.13 NS 
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Figure 3.7 below shows the CD4
+
 subset distribution comparison between healthy 
controls and patients. In both the patient and control group, naïve cells were the 
most abundant, followed by the effector memory cells. It was expected that the 
percentage of naïve cells would be greater in the control group, and the percentage 
of effector memory cells would be greater in the patient group, however this was not 
the case. The terminally differentiated cells in the patient group are greater than the 
central memory cells, and this is expected as there is on-going immune activation 
leading to more exhausted cells.    
 
 
Figure 3.7 Comparison of CD4
+
 T-cell subset distributions between healthy controls and 
patient group. Naïve cells were the most abundant cell type in both groups followed by the Effector 
memory cells. The control group had more central memory cells than terminally differentiated effector 
memory cells which is expected, whereas the patient group had more terminally differentiated effector 
memory cell expression than central memory cells. 
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3.4 Cytokine expression on CD4
+
 T-cells 
In figure 3.8 below cytokine expression of the total CD4
+
 T-cell population was 
compared between the healthy control and patient group. In table 3.5 below, single 
expression of IFN-γ and IFN-γ+TNF-α+ dual expression was similar in the two groups 
and although the TNF-α expression was higher in the patient group, the difference in 
expression was not significant. 
 
Table 3.5 T-test of cytokine expression 
P-value >0.005 = not significant (NS) 
  
 
Cytokine 
Median % 
      Control                            Patient 
 
 
P - value 
IFN-γ 2.960 2.370 0.2800 (NS) 
TNF-α 1.340 2.415 0.1729 (NS) 
IFN-γ+TNF-α+ 0.5400 0.8550 0.3961 (NS) 
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Figure 3.8 Comparison of cytokine expression between healthy controls and patients. IFN-γ 
expression was higher in the control group (median %IFN-γ 2.960 ± 3.51 vs. patient 2.370 ± 2.07; 
p=0.2800), whereas TNF-α expression was higher in the patient group (median %TNF-α 2.415 ± 2.60 
vs. control 1.340 ± 1.86; p=0.1729). Dual expression of IFN-γ and TNF-α was similar in the two 
groups, although slightly higher in the patient group (control median %IFN-γ
+
TNF-α
+
 0.5400 ± 0.36 vs. 
patient 0.8550 ± 0.60; p=0.3961).  
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** 
3.5 Effect of stimulation on CD4
+
 T- cells 
 
3.5.1 Effect of stimulation on IFN-γ expression in the patient group 
In Table 3.6 IFN-γ expression was compared between the three stimulation 
conditions. The negative control expressed significantly more IFN-γ than the other 
two conditions. Figure 3.9 below shows the effect of stimulation on IFN-γ expression. 
 
Table 3.6 Effect of stimulation on IFN-γ on total CD4+ T-cell population within the 
patient group 
 BL%IFN-γ SEB%IFN-γ E/C%IFN-γ 
Median 3.475 2.520 2.370 
P-value (<0.05) = 0.0015 
BL %IFN-γ   vs. SEB %IFN-γ= No 
BL %IFN-γ vs. E/C %IFN-γ= Yes ** 
SEB %IFN-γ vs. E/C %IFN-γ   = Yes * 
BL = Baseline (negative control), SEB = Staphylococcus Enterotoxin B (positive control), E/C = ESAT6/CFP10  
Effect of stimulation  - IFN
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Figure 3.9CD4
+
 T-cells were stimulated with TB antigens ESAT6 and CFP10 and the effect this 
had on the IFN-γ cytokine expression was recorded. The results indicate that stimulating cells 
significantly decreased IFN-γ expression. 
NS * 
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NS 
** 
3.5.2 Effect of stimulation on TNF-α expression in the patient group 
In Table 3.7 TNF-αexpression was compared between the three stimulation 
conditions. The E/C test condition had the least cytokine expression and was 
significantly less than the positive control. Figure 3.10 below shows the effect of 
stimulation on TNF-α expression. 
 
Table 3.7Effect of stimulation on TNF-α on total CD4+ T-cell population within the 
patient group 
 BL % TNF-α SEB % TNF-α E/C% TNF-α 
Median  3.510 4.500 2.415 
P-value (<0.05) = 0.0064 
BL % TNF-α    vs. SEB % TNF-α    = No  
BL % TNF-α    vs. E/C % TNF-α     = No 
SEB % TNF-α vs. E/C % TNF-α     = Yes ** 
BL = Baseline (negative control), SEB = Staphylococcus Enterotoxin B (positive control), E/C = ESAT6/CFP10  
 
 
 
Figure 3.10CD4
+
 T-cells were stimulated with Tuberculosis antigens ESAT6 and CFP10 and the 
effect this had on the TNF-α cytokine expression was recorded. The positive control had the most 
cytokine expression and expressed significantly more TNFα than in the E/C test cond ition 
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3.5.3 Effect of stimulation on dual cytokine expression in the patient group 
In Table 3.8 IFN-γ+ TNF-α+ expression was compared between the three stimulation 
conditions. There was no statistical difference in cytokine expression between the 
three conditions. Figure 3.11 below shows the effect of stimulation on IFN-γ+ TNF-α+ 
dual expression.  
 
Table 3.8 Effect of stimulation on % IFN-γ+ TNF-α+on total CD4+ T cell population 
within the patient group 
 BL % IFNγ+ TNFα+ SEB % IFNγ+ TNFα+ E/C % IFNγ+ TNFα+ 
Median 0.9650 1.000 0.8550 
P-value (<0.05) = 0.2231 
BL % IFNγ+ TNFα+       vs. SEB % IFNγ+ TNFα+ = No 
BL % IFNγ+ TNFα+       vs. E/C % IFNγ+ TNFα+   = No 
SEB % IFNγ+ TNFα+  vs. E/C % IFNγ+ TNFα+    = No 
BL = Baseline (negative control), SEB = Staphylococcus Enterotoxin B (positive control), E/C = ESAT6/CFP10  
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Figure 3.11CD4
+
 T-cells were stimulated with Tuberculosis antigens ESAT6 and CFP10 and the 
effect this had on the IFNγ
+
TNFα
+
 cytokine expression was recorded. The three conditions 
displayed similar dual cytokine expression with no statistical difference in the median values. 
NS 
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3.5.4 Effect of stimulation on IFN-γ expression in the control group 
In table 3.10 below IFN-γ expression was compared between the three stimulation 
conditions. The negative control expressed significantly more IFN-γ than the other 
two conditions. Figure 3.12 below shows the effect of stimulation on IFN-γ 
expression within the healthy control group. 
 
Table 3.9Effect of stimulation on IFN-γ on total CD4+ T-cell population within the 
healthy control group 
 BL%IFN-γ SEB%IFN-γ E/C%IFN-γ 
Median 5.110 3.900 2.960 
P-value (<0.05) = <0.0001 
BL %IFN-γ   vs. SEB %IFN-γ= No 
BL %IFN-γ vs. E/C %IFN-γ= Yes *** 
SEB %IFN-γ vs. E/C %IFN-γ   = Yes * 
BL = Baseline (negative control), SEB = Staphylococcus Enterotoxin B (positive control), E/C = ESAT6/CFP10  
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Figure 3.12CD4
+
 T-cells were stimulated with TB antigens ESAT6 and CFP10 and the effect this 
had on the IFN-γ cytokine expression was recorded. The box and whisker plots show a significant 
difference in IFN-γ between BL and EC as well as SEB and EC 
NS * 
*** 
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3.5.5 Effect of stimulation on TNF-α expression in the control group 
In table 3.10 below TNF-α expression was compared between the three stimulation 
conditions. The E/C test condition had the least cytokine expression and was 
markedly less than the positive control. Figure 3.13 below shows the effect of 
stimulation on TNF-α within the healthy control group. 
 
Table 3.10 Effect of stimulation on TNF-α on total CD4+ T cell population within the 
healthy control group 
 BL % TNF-α SEB % TNF-α E/C% TNF-α 
Median  2.270 2.200 1.340 
P-value (<0.05) = 0.3621 
BL % TNF-α    vs. SEB % TNF-α    = No  
BL % TNF-α    vs. E/C % TNF-α     = No 
SEB % TNF-α vs. E/C % TNF-α     = No 
BL = Baseline (negative control), SEB = Staphylococcus Enterotoxin B (positive control), E/C = ESAT6/CFP10  
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Figure 3.13CD4
+
 T-cells were stimulated with Tuberculosis antigens ESAT6 and CFP10 and the 
effect this had on the TNF-α cytokine expression was recorded. Although the E/C condition had 
the least cytokine expression it was not statistically lower than the two control conditions.  
NS 
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3.5.6 Effect of stimulation on dual cytokine expression in the control group 
In table 3.11 below IFN-γ+ TNF-α+dual expression was compared between the three 
stimulation conditions. Although the cytokine expression was similar in the negative 
and positive control, there was a statistical difference in expression between the 
negative control and the E/C condition. Figure 3.14 below shows the effect that 
stimulation had on IFNγ+TNFα+ dual expression within the control group. 
Table 3.11Effect of stimulation on IFNγ+TNFα+ on total CD4+ T-cell population within 
the healthy control group 
 BL % IFNγ+ TNFα+ SEB % IFNγ+ TNFα+ E/C % IFNγ+ TNFα+ 
Median 0.8500 0.8300 0.5400 
P-value (<0.05) = 0.0307 
BL % IFNγ+ TNFα+       vs. SEB % IFNγ+ TNFα+ = No 
BL % IFNγ+ TNFα+       vs. E/C % IFNγ+ TNFα+   = Yes * 
SEB % IFNγ+ TNFα+  vs. E/C % IFNγ+ TNFα+    = No 
BL = Baseline (negative control), SEB = Staphylococcus Enterotoxin B (positive control), E/C = ESAT6/CFP10  
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Figure 3.14CD4
+
 T cells were stimulated with Tuberculosis antigens ESAT6 and CFP10 and the 
effect this had on the IFNγ
+
TNFα
+
 cytokine expression was recorded. The cytokine expression in 
the negative and positive control was almost identical; however the negative control was statistically 
higher than the EC test condition. 
NS NS 
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3.6 TIM3 expression on total CD4
+
 T-cell subsets 
TIM3 showed no statistical difference in expression within the CD4
+
 subsets in both 
the patient and control group (data not shown). In table 3.12 below central memory 
cells expressed the most TIM3 in both groups; however it was not significantly higher 
than the other cell groups. In active TB, it is expected that effector memory cells 
would express the most TIM3 and patients with HIV would have terminally 
differentiated CD4
+
 cells expressing the most TIM3, but this was not the case.  
 
Table 3.12 TIM3 expression on CD4
+ 
T-cell subsets in patient group 
 Naïve  Central 
memory 
Effector 
memory 
Terminally 
differentiated  
Median 0.1700 0.4450 0.1800 0.2600 
P-value (<0.05) = 0.1511 
TN %TIM3 vsTCM %TIM3 = No  
TN %TIM3 vsTEM %TIM3 = No 
TN %TIM3 vs TDEM %TIM3 = No 
TCM %TIM3 vsTEM %TIM3 = No 
TCM %TIM3 vs TDEM %TIM3 = No 
TEM %TIM3 vs TDEM %TIM3 = No 
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Chapter 4 – Discussion 
 
In this study we aimed to develop and optimise a blood based flow cytometry assay 
in order to detect cytokines released from CD4
+
 T-cells in patients with active TB 
compared to a control group of healthy individuals. Development and optimisation of 
such an assay would aid in elucidating optimal reagent volumes and concentrations, 
while maximising the number of tests that can be performed, thereby lowering the 
effective cost-per-patient. It would allow us to generate intracellular cytokine (TNF-α 
and/or IFN-ү) profiles of CD4+ T-cell populations following exposure to TB specific 
antigens in order to distinguish between active and latent TB in both TB and in some 
instances HIV and TB co-infected individuals. 
 
4.1 Optimisation of a whole blood flow cytometry assay 
From the literature, most flow based TB assays have been performed on PBMC’s 
rather than whole blood. For the purpose of this study, whole blood has been used 
for analysis in order to allow for a faster turnaround time but also reduce labour and 
cost and is performed in an environment close to in vivo. For the optimization 
aspects we evaluated incubation temperatures (37
o
C vs. 4
o
C) on CD4
+
 T-cell yield 
as well as experimental conditions. We also aimed to determine whether staining 
with surface markers before or after permeabilization has an effect on CD4
+
 T-cell 
yield and to determine antibody volumes. From our results, in chapter 3, section 
3.3.1 as observed in figure 3.2, page 39, no significant differences were observed 
between incubation temperatures of 37
o
C vs. 4
o
C, therefore all future incubation 
experiments were conducted at 37
o
C. Regarding the staining of surface marker prior 
or after permeabilization, results observed showed that staining prior to 
permeabilization yielded the best results as observed in chapter 3, section 3.3.2, 
figure 3.3, page 40. The antibody titration aspect formed the bulk part of the 
optimization and there was three criteria used to determine antibody volume, 
namely: 1) statistical analysis, 2) visual analysis and 3) signal to noise ratio. In using 
these criteria we were able to optimise most of the antibodies in the panel except for 
TIM3-PC7 and CD45-ECD. These antibodies only had one population of cells that 
had a high MFI, and because of this the visual analysis and signal to noise ratio 
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could not be used. The manufacturer suggests using 5µl of TIM3-PC7, but 
statistically there was no difference between 4µl and 5µl, hence we used 4ul of 
TIM3-PC7 in the assay. The suggested volume of CD45-ECD is 10µl, however there 
was no statistical difference between 10µl and 8µl; hence we used 8µl CD45-ECD in 
the assay. For all the other antibodies in our staining panel, less volume per reaction 
recommended by the manufacturer was used (see chapter 2, section 2.6.1, Table 
2.1, page 28). The titrations performed maintained optimal staining of our cells, 
which subsequently reduced the effective cost per sample. 
 
4.2 CD4
+
 T-cell subset distribution 
As per the gating strategy in Chapter 2, section 2.8,CD4
+
 T-cells were further 
delineated into the following four subsets, namely: naïve cells (TN), central memory 
(TCM), effector memory (TEM) and terminally differentiated effector memory cells 
(TDEM). According to Rovina et al. (2013) polarisation of the CD4
+
T-cell compartment 
towards a specific subset may be indicative of a disease state, and certain effector 
molecules, such as cytokines, are associated with different stages of disease, such 
as active, or latent disease(Rovina et al., 2013). Furthermore, Chiacchio et al. (2014) 
has found that HIV uninfected patients have a higher proportion of MTB-specific TEM 
T-cells, and a lower proportion of TCM CD4
+
 T-cells in active TB patients, compared 
to those with latent MTB infection (Chiacchio et al., 2014). Likewise, Petruccioli et al. 
(2013) also showed that during active TB infection, effector CD4
+
 T-cells are 
expanded, and there is a higher proportion of antigen-specific TEM T-cells, while the 
proportion of TCM CD4
+
 T-cells is reduced, compared to that of latently-infected 
individuals (Petruccioli et al., 2013). However; our results showed that naïve cells 
were the most abundant cell type in both the control and patient group, and their 
relative proportions were not statistically different from one another. In both patients 
and controls there was a higher expression of TEM CD4
+
 T-cells, followed by TCM T-
cells. This was consistent with literature, although this was not statistically significant. 
The population with the lowest relative frequency was that of the terminally 
differentiated subset, which was expected in the control group and in HIV negative 
individuals; however one would expect to see an increased frequency of TDEM T-cells 
in HIV
+
 individuals. Due to the fact that the HIV
+
 cohort of patients were very few in 
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number, there was no statistically-significant increase in the TDEM subset , however a 
larger sample size may confirm this finding. 
 
4.3 IFNү – single or dual expression) 
IFN-ү in conjunction with TNF-α control intracellular infections. The differential 
expression patterns of these cytokines allows one to classify TB infection as being 
either active or latent(Kaufmann, 2001). These two cytokines work synergistically to 
ward off pathogens and the expression of either TNF-α alone, or both TNF-α and 
IFN-ү is associated with active TB disease. On the contrary, polyfunctional cells 
expressing TNFα+IFNү+IL-2+ are found in patients with latent TB infection (LTBI) or in 
patients who are on TB treatment (Jasenosky et al., 2015). As seen in chapter 3, 
section 3.5, figure 3.9, page 50, we compared the expression of IFN-ү between 
healthy controls and the patient group. IFN-ү expression was almost similar in the 
two groups, although slightly higher in the control group, the difference in expression 
was not statistically significant (p = 0.2800).  
When individuals are in states of long-term immune control, as in the case of treated 
TB or latent infection or BCG vaccination, these patients may have an immunological 
profile that is dominated by dual IFNү+IL-2+ secreting effector memory T-cells 
(Rovina et al., 2013). As a means to save costs we did not include IL-2 in our 
staining panel making it difficult to assess whether the IFN-ү expression was indeed 
single expression or whether it was co-expressed with IL-2. Our control group 
consisted of National Health Laboratory Services (NHLS) staff members from the 
Division of Haematology, Tygerberg Hospital, leading to the assumption that these 
subjects have been exposed to TB and are most likely immunised. We would 
therefore expect to see the increased dual expression of IFN-ү+IL-2+, however, since 
we do not have IL-2
+
 in our staining panel one cannot determine whether the 
increased IFN-ү expression we see in our control group is increased as a single 
parameter or whether it is increased together with IL-2, which would then justify our 
findings.  
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4.4 TNFa expression is increased in active TB 
Observations from literature by (Harari et al., 2011) and Rovina et al (2013), have 
concluded that TNFα-expressing MTB-specific CD4+ T-cells (“single-positive” cells) 
were increased in subjects with active TB. This confirms our finding as seen in 
chapter 3, section 3.5, figure 3.9, page 50, that there was a trend towards increased 
TNF-α expression in the patient group (median 2.415, SD = 2.606), and although it 
was not significantly increased (p = 0.1729) we can conclude that based on this 
result our findings are in line with literature. 
 
4.5 Presence of increased bifunctional CD4
+
 T-cells is correlated with active 
disease 
In our study we have shown in chapter 3, section 3.5, figure 3.9, page 50, that dual 
expression of IFN-үand TNF-α on CD4+ T-cells is higher in the patient group than in 
the control group, although the difference was not statistically significant (p = 
0.8550). This is consistent with data reported by Petruccioli et al. (2013) that stated 
MTB-specific IFNү+TNFα+ CD4+ T-cells were significantly increased in patients with 
active TB compared to LTBI patients (p=0.008). Chiacchio et al (2014) in their study 
showed that IFNү+TNFα+ CD4+ T-cells associated with HIV-TB; however we had too 
few HIV
+
 patients in our study group to compare to their findings.  
 
4.6 Stimulation with TB antigens has an effect on IFN-ү production 
To determine whether cell stimulation had an effect on cytokine production, we 
compared median expression between the three stimulation conditions i.e. 
unstimulated baseline (“baseline”), SEB – positive control and TB antigens ESAT6 & 
CFP10 (E/C). We found that IFN-ү production was significantly decreased in all 
stimulation conditions in both the control and patient groups. TNF-α production was 
significantly down regulated in the patient group and although there was decreased 
production in the control group, it was not of significance. Similarly, there was a 
significant decrease in IFNү+TNFα+ dual expression within the control group, 
however; the decrease in IFNү+TNFα+ dual expression within the patient group was 
not significant. From this we can conclude that stimulating CD4
+
 T-cells does 
decrease the production of cytokines and whether the effect of stimulation was 
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significant or not, we could still rely on the cytokine production and expression 
patterns to classify our results. 
 
4.7 TIM3 expression on CD4
+
 T-cell subsets 
TIM3 is conjugated to fluorochrome PC7, resulting in bright expression of the single 
TIM3 population. Jayaraman et al (2016) has shown in their study that TIM3 has 
bimodal expression with clear separation of the negative and the positive population; 
however this was not the case in our study (Jayaraman et al., 2016).   
All four CD4
+
 T-cell subsets had similar TIM3 expression. Central memory cells had 
slightly higher expression but it was not significant (p=0.1511). As TB disease 
progresses you would expect to see TDEM T-cells expressing TIM3 as these cells are 
functionally exhausted. Also, with our patient cohort being hospital patients with co-
infections, we expected to see higher levels of TIM3 within this group, however the 
TIM3 expression was similar (controls = 3.300, patients = 3.830) indicating no 
significant difference between the two groups. It may be useful to reinvestigate the 
TIM3 expression on a larger cohort of patients and also to compare the TIM3 
expression between HIV
+
 and HIV
-
patients. 
 
4.8 Limitations of study 
Our healthy control cohort was NHLS staff members within the TBH. All control 
subjects recruited in this study completed a TB exposure questionnaire which is 
designed to rule out the chance of the person having active TB, however; it does not 
rule out latent infection due to the absence of reportable symptoms. Working in a 
hospital environment exposes you to infections such as TB, and based on this one 
can assume that it is possible for the control subjects to have been exposed to TB 
and possibly have LTBI. Rovina et al., (2013) has shown that polyfunctional 
TNFα+IFNү+IL-2+CD4+ T-cells are associated with LTBI. Since we did not include IL-
2 in our staining panel we cannot confidently say that our healthy controls are not 
producing IL-2. Our control cohort was not tested for LTBI either as this would’ve 
added to the cost of the study significantly. For this reason we cannot distinguish 
between active and LTBI as we cannot confidently say whether our control group is 
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healthy or has LTBI to compare to the results of our patient cohort. However, taking 
into account the area and target population one can assume that the control group 
would have LTBI. 
The patients for our study group were patients from TBH. In order to use patients 
from local peripheral clinics required a lengthy application process to the Western 
Cape Department of Health and our timeline could not accommodate such a 
process. Patients admitted to TBH with active TB however were more than often 
patients with TB reactivation. Also, these patients were often on empirical TB 
treatment. Thirty three percent (6/18) of our patient cohort had HIV and this resulted 
in very low CD4
+
 T-cell counts for these patients. Since CD4
+
 T-cells were our cells 
of interest, we often only managed to acquire 9-12 CD4
+
 T-cells, making it 
impossible to further analyse that data as that would lead to our results being 
skewed and working with such low numbers of CD4
+
 T-cells can lead to unreliable 
results. These patients were subsequently excluded from our data analysis. Our 
patient group consisted mainly of generally very ill patients with underlying diseases 
or co-infections aggravating the TB and this resulted in a very lengthy recruitment 
process as newly diagnosed TB, off-treatment patients are very seldom sent to a 
tertiary institution such as TBH. On 3 occasions where potential patients had newly-
diagnosed TB and had not started TB treatment yet, these patients were so ill due to 
their co-infections, that they were unable to communicate and give informed consent. 
A major limitation of this study was our sample size, because with only 18 patients it 
was impossible to statistically determine cut-off values for our positive and negative 
results. Although we only needed 8 patients for statistical power, as determined by 
the statistician, it would’ve been interesting to set cut-off values to validate our 
findings in the patient cohort. 
 
4.9 Summary of results and the way forward 
In summary, the optimisation of this assay was challenging and lengthy, however it 
yielded the desired results. In future we will be able to use less antibody per assay 
and this would decrease the cost of future work. Revision of the staining panel may 
be necessary so as to include markers such as IL-2. Other studies have heavily 
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relied on IL-2 expression to confirm whether the IFN-ү and/or TNF-α expression is 
indeed single expression and not co-expressed with IL-2 as this may change the 
disease status completely. However; a trend towards increased levels of TNF-α 
expression in our patient cohort is in line with the findings in other studies. 
The increased expression of single IFN-ү in our control cohort can be suggestive of 
our control subjects being vaccinated with BCG or being latently infected with TB. 
Both scenarios can be used to describe these subjects, but we cannot confirm this. 
In future it would be advisable to test the healthy control group for LTBI using the 
QuantiFERON-TB Gold In –Tube test (QFT-GIT) in order to draw a clear line 
between healthy persons and those with LTBI. Study subjects should also indicate 
whether they have been previously vaccinated, although as most people are 
vaccinated as infants, it may be difficult to get this kind of information. Although we 
had slightly higher IFN-ү expression (not significant) in our control group as opposed 
to our patient group, it would be advisable to still include IL-2 in our staining panel to 
strengthen our findings. 
In addition, patients should be recruited from the local community clinic which would 
ensure that these patients are newly diagnosed TB cases, not on treatment. This 
would speed up the recruiting process as large numbers of patients visit the clinics 
on a daily basis. This would also make it easy to recruit newly diagnosed HIV
+ 
patients in order to differentiate between HIV
+
TB
+
 and HIV
-
TB
+
 patients in future 
studies. Furthermore, these patients could be tested post treatment to compare the 
cytokine expression patterns and compare it to literature.  It would enhance this 
study greatly if we could recruit more patients in order to determine sample cut-offs, 
to include IL-2 in our staining panel and to screen our healthy patient cohort to 
differentiate between healthy and LTBI. 
The flow cytometry antibody panel would have to be redesigned to accommodate 
TIM3 conjugated to a different fluorochrome as TIM3 would indicate those T-cells 
that are functionally exhausted, and this would assist in classifying our results. 
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4.10 Conclusion 
In our study we went with the whole blood approach to differentiate between active 
and latent TB within 24 hours. Our assay measured IFN-ү and TNF-α simultaneously 
at the single cell level which is important as certain cytokine profiles have been 
shown to be associated with specific disease profiles. Through optimisation we could 
determine that this assay may be performed from less than 500µl of whole blood and 
with results being available by the following day, this assay holds the promise for 
being able to be implemented in a routine setting.   
Flow cytometry is a high-throughput technique that can be applied to a number of 
diagnostic areas. Although it is quite technical, careful controlling of instrument and 
experimental factors allows for high-quality reproducible results. Furthermore, 
stimulation assays such as the one described here are routinely used in determining 
immune responses in vaccine trials, and have been shown to provide reliable results. 
These types of assay are, however, time-consuming and relatively expensive 
compared to conventional TB diagnostic tests, although this may be more a 
reflection of economies-of-scale rather than pure cost analysis. With that said, 
stimulation-flow cytometry assays are currently the only method that is able to 
enumerate antigen-specific T-cells while delineating into T-cell subsets. With 
ongoing development of new instruments and reagents, it is possible that more data 
per patient can be generated in a single assay, for a decreased price. After careful 
titration of antibodies, a viability marker and a robust gating strategy, this assay has 
proven its suitability and usefulness in our set-up.  
This study has shown an increase in IFN-γ expression within our patient cohort 
although we could not distinguish between exposure through immunisation or latent 
infection in the control group. Future studies would have to determine both the 
vaccination status of the control group, and whether or not they have latent TB. It 
was interesting to note the trend towards increased expression levels of TNF-α only 
within the patient group, as this is suggestive of active TB, however; a larger sample 
size is needed to confirm this. It is desirable to compare the results of an HIV
+
TB
+
 
cohort to that of an HIV
-
TB
+
 cohort, as an increase in bifunctional MTB-specific CD4
+
 
T-cells would be seen in those patients with HIV. Unfortunately, in a hospital set-up 
such as in TBH, patients with HIV
+
TB
+
 have very low CD4
+
 T-cell counts, thereby 
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making analysis on these patients nearly impossible. A cohort of HIV
+
TB
+
 patients 
with CD4
+
 T-cell counts above 350cells/µl would be advisable in future studies. 
Furthermore, including markers such as IL-2 in the antibody staining panel may 
assist in differentiating between active and latent TB which in this setting is 
necessary due to the high incidence of HIV and TB co-infection. By addressing the 
limitations in this study, this assay has the potential to significantly impact the current 
on-going diagnostic challenges in accurately diagnosing latent TB, while ensuring 
turnaround times of less than 24 hours. 
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Addendum 1 
 
Statistical determination of optimal antibody volumes 
 
ROW # Antibody Comparison (µl) MFI mean difference P value 
1 CD4-APC 1 vs. 2 -38.04 0.0026 **  
2  2 vs. 4 -24.97 0.0036 **  
3  4 vs. 6 -18.19 0.0647 (NS)  
4  6 vs. 8 -5.500 0.0022 ** 
5  8 vs. 10 -22.25 0.4394 (NS) 
APC –Allophycocyanin 
 
ROW # Antibody Comparison (µl) MFI mean difference P value 
1 CD45-ECD 1 vs. 2 -50.55 0.0316 *  
2  2 vs. 4 -11.29 0.0475 *  
3  4 vs. 6 -60.51 0.0016 ** 
4  6 vs. 8 3.843 0.0465 * 
5  8 vs. 10 3.878 0.0151 * 
ECD - PhycoerythrinTexas Red-X 
 
ROW # Antibody Comparison (µl) MFI mean difference P value 
1 CD27-APC 750  1 vs. 2 -5.083 0.0031 **  
2  2 vs. 4 -2.293 0.0199 *  
3  4 vs. 6 -0.3967 0.2776 (NS) 
4  6 vs. 8 0.3733 0.2200 (NS) 
5  8 vs. 10 0.1000 0.7390 (NS) 
APC750 –Allophycocyanin 750 
 
ROW # Antibody Comparison (µl) MFI mean difference P value 
1 TIM3-PC7  1 vs. 2 -12.81 0.0017 **  
2  2 vs. 3 -6.573 0.0020 **  
3  3 vs. 4 -7.303 0.0039 ** 
4  4 vs. 5 -8.110 0.0820 (NS) 
PC7 - Phycoerythrin-Cyanin 7 
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ROW # Antibody Comparison (µl) MFI mean difference P value 
1 TNFα-PE 6 vs. 8 -0.2500 0.0494 *  
2  8 vs. 10 -0.8267 0.0116 *  
3  10 vs. 12 -0.1000 0.2300 (NS)  
4  12 vs. 14 -0.09000 0.5949 (NS) 
5 
6 
7 
 14 vs. 16 
16 vs. 18 
18 vs. 20 
-0.4767 
-0.5067 
-0.2700 
0.0508 (NS) 
0.0666 (NS) 
0.0968 (NS) 
PE - Phycoerythrin 
 
ROW # Antibody Comparison (µl) MFI mean difference P value 
1 IFN-γ-FITC 6 vs. 8 -0.02000 0.7007 (NS)  
2  8 vs. 10 -0.05000 0.0377 *  
3  10 vs. 12 -0.01000 0.4226 (NS)  
4  12 vs. 14 -0.04000 0.0202 * 
5 
6 
7 
 14 vs. 16 
16 vs. 18 
18 vs. 20 
-0.03333 
-0.03333 
-0.03333 
0.0099 ** 
0.0099 ** 
0.0099 ** 
FITC - Fluorescein isothiocyanate 
 
ROW # Antibody Comparison (µl) MFI mean difference P value 
1 CD45RO-BO  0.5 vs. 1 -0.4033 0.3779 (NS)  
2  1 vs. 1.5 0.7167 0.0313 *  
3  1.5 vs. 2 -0.8067 0.0287 *  
4  2 vs. 2.5 -0.4000 0.0970 (NS) 
5 
6 
7 
 2.5 vs. 3 
3 vs. 4 
4 vs. 5 
-0.2367 
-0.2867 
-0.05667 
0.0715 (NS) 
0.0459 * 
0.1425 (NS) 
BO – Brilliant Orange 
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Addendum 2 
 
Determination of optimal antibody volume using the S:N ratio.                                 
For antibodies CD45-ECD and TIM3-PC7 the S:N ratio could not be used as both 
these antibodies had 100% MFI positivity. 
 
Antibody Volume (µl) S:N ratio MFI of negative 
population 
MFI of positive 
population 
CD4 1 48.09 2.06 99.06 
 2 45.39 2.52 114.40 
 4 26.44 3.27 86.45 
 6 31.21 3.21 100.18 
 8 19.36 3.54 68.54 
 10 15.003 3.64 54.61 
 
 
Antibody Volume (µl) S:N ratio MFI of negative 
population 
MFI of positive 
population 
CD27 1 10.08 0.73 7.36 
 2 9.495 1.09 10.35 
 4 8.33 1.32 11.00 
 6 7.50 1.42 10.65 
 8 6.97 1.50 10.46 
 10 6.98 1.51 10.54 
 
 
Antibody Volume (µl) S:N ratio MFI of negative 
population 
MFI of positive 
population 
CD45RO 0.5 10.16 0.45 4.57 
 1 9.89 0.53 5.24 
 1.5 9.16 0.62 5.68 
 2 9.08 0.74 6.72 
 2.5 8.52 0.81 6.90 
 3 
4 
5 
7.34 
6.29 
5.44 
0.90 
1.02 
1.10 
6.61 
6.42 
5.98 
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Antibody Volume (µl) S:N ratio MFI of negative 
population 
MFI of positive 
population 
IFN-γ 6 1.76 0.74 1.30 
 8 1.59 0.75 1.19 
 10 1.62 0.78 1.27 
 12 1.64 0.76 1.25 
 14 1.76 0.75 1.32 
 16 
18 
20 
1.76 
1.79 
1.77 
0.76 
0.76 
0.79 
1.34 
1.36 
1.40 
 
 
Antibody Volume (µl) S:N ratio MFI of negative 
population 
MFI of positive 
population 
TNF-α 6 5.76 0.54 3.11 
 8 8.80 0.36 3.17 
 10 9.80 0.36 3.53 
 12 10.05 0.37 3.72 
 14 10.55 0.38 4.01 
 16 
18 
20 
12.34 
13.26 
8.14 
0.35 
0.34 
0.61 
4.32 
4.64 
4.97 
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